january 2014 curriculum vita richard m. kostrzewa, ph.d. · r.m. kostrzewa, ph.d. journal and book...

R.M. Kostrzewa, Ph.D.

January 2014

CURRICULUM VITA

Richard M. Kostrzewa, Ph.D.

Professor, Department of Biomedical Sciences

Quillen College of Medicine PH: +1 423 439-6321

East Tennessee State University FAX: +1 423 439-8044

P.O. Box 70,577 Email: [email protected]

Johnson City, TN 37614-1708

Personal

United States Citizen

Married

Education/Degrees

Philadelphia College of Pharmacy & Science B.S. Chemistry 1965

Philadelphia College of Pharmacy & Science M.S. Pharmacology 1967

University of Pennsylvania, Philadelphia, PA Ph.D. Pharmacology 1971

Medical University of Silesia, Katowice, Poland Doctor Honoris Causa 2005

Positions

Research Pharmacologist, Veterans Administration Medical Center, New Orleans, LA, 1971-75

Adjunct Assistant Professor of Pharmacology, Tulane University Medical Center, New Orleans, LA,

1974-76; Adjunct Instructor, 1972-73

Graduate Faculty, Department of Psychology, University of New Orleans, New Orleans, LA,

1974-77

Assistant Professor of Physiology, Louisiana State University Medical Center, New Orleans, LA,

1975-78

Professor of Pharmacology/Biomedical Sciences, Quillen College of Medicine, East Tennessee State

University, 1984- ; Associate Professor, 1978-84

Visiting Professor, Medical University of Silesia in Katowice, Poland, 1997-2003

Societies

Neurotoxicity Society, Founding Board, President (2001-03), Past-President (2003-05),

Treasurer (2005- Dec 2011), Council (2012-2014)

American Society of Pharmacology and Experimental Therapeutics (1975- present)

Federation of American Societies for Experimental Biology (1975-90)

Experimental Biology (1990- present)

Society for Neuroscience (1973- present); Int’l Brain Research Organization (1984- present)

Orthoquinone Club (1997- 2001)

Appalachian Chapter, Society for Neuroscience: Organizer (1979)

President-Elect (1986, 1988), President (1980, 1987, 1989-2003)

Southeastern Pharmacology Society (1986-96; Councilor, 1989-91; 1994-6)

Society of Toxicology (1994-99)

Greater New Orleans Chapter, Society for Neuroscience: Organizing Committee (1973), Secretary

(1976), President-Elect (1977), President (1978)

Histochemical Society (1980-89)


TEACHING

Medical Pharmacology Course, East Tennessee State University (ETSU)

1980-present ; Course Director, 1985, -86, -87; -96, -97; 2005 & 2006; 2008, 2009.

Medical Neuroscience Course, ETSU College of Medicine, 2002-present

Medical Pharmacology Course, Medical University of Silesia, Katowice, Poland

approx. 10 lectures annually, 1997-2001

Nursing Pharmacology Course, ETSU, 1983-87

Clinical Pharmacology Course, ETSU, 1982-94

Graduate Biomedical Sciences Core Course, 2001-2004

Graduate Neurochemistry Course, ETSU, 1981, -83, -85, -87, -89

Graduate Neuropharmacology Course, ETSU

Course Director, 1982, -84, -86, -88, -90, -92, -94, -99, -01

Graduate Autonomic Pharmacology Course, ETSU, 1982, -87, -89, -91, -93, -96, -98

Graduate Pathophysiology Course, ETSU, lecturer, 2010, 2011

Graduate Toxicology Course, ETSU, 1983, -86, -90, -92, -95, -97

Pharmacology Journal Club, ETSU, 1985-present; Director, 1988-2003

Pharmacology Seminar, ETSU, 1972-present; Director, 1988-2001

Survival Skills and Ethics in Science, ETSU, Organizer, 1997; Director, 1998

Dental Physiology Course, Louisiana State Univ. Medical Ctr (LSUMC), 1975-78

Medical Pharmacology Course, LSUMC, 1976

Medical Pharmacology Course, Tulane Medical Center, 1973-75

Undergraduate Pharmacology Course, Tulane University, 1974

Graduate Pharmacology courses, Tulane and LSUMC, 1972-78

Undergraduate Psychology Course, University of New Orleans, 1975

GRADUATE ADVISING at ETSU

Dr. Ellen Kunkel-Bagden, Ph.D. Advisor, Dissertation defense, 1985

Ms. Teresa G. White, M.S. Advisor, Thesis defense, 1988

Dr. M. Iqbal Saleh, Ph.D. Advisor, Dissertation defense, 1988

Dr. Anwar Hamdi, Ph.D. Advisor, Dissertation defense, 1990

Dr. Li Gong, Ph.D. Advisor, Dissertation defense, 1993

Dr. Nuoyu Huang, Ph.D. Advisor, Dissertation defense, 1995

Thesis Advisory Committees for:

Dr. Tim A. Robert, 1978-80 Toh Gang, 2011-

Dr. Jacob Dunbar, 1987-92 Avinash Thirumalai, 2011-

Dr. T. Scott Thurmond, 1990-95 Joseph Wu, 2011-

Dr. Yu-Li Liu, 1993- 97 Ashley Brianna Sheppard, 2012-

Mr. Thomas Rudolph, 1995-96

Dr. Rachel Qualls, 1995-2000

Dr. Sandeep Saroch, 1996-7

Dr. Xuwan Liu, 1999-2003

Dr. David Burrows, 2002-04

Dr. X Xu, 2004-07

Kimberly Thompson, 2007-09


RESEARCH ASSOCIATES

Dr. M. Blair Clark, NIH Postdoctoral Fellowship, 1977-79

Dr. Hideki Fukushima, Dept. Pediatrics, Tottori University, Japan, sabbatical 1978-80

Dr. Craig T. Harston, Postdoctoral Fellow, 1978-81

Dr. Dolores Klisans-Fuenmayor, Dept. Physiology, University of Venezuela, Caracas, Venezuela, sabbatical, 1982-83

Prof. Dr. Ryszard Brus, Chairman, Department of Pharmacology, Medical University of Silesia, Poland. Visiting

Scientist: 1981, -91, -92, -93, -94, -95, -96, -97

Prof. Dr. Andrzej Plech, Medical University of Silesia, Poland. Visiting Scientist, 1992

Ms. Tanisha Douglas, McNair Fellowship, 1992

Mr. Ed Abell, American Society of Pharmacology (ASPET) Fellowship, 1992

Dr. Dong Yugang, Sun Yat-sen University, China, sabbatical, 1997

Dr. Joanna Oswiecimska, Medical University of Silesia, Poland. Visiting Scientist, 2000

Ms. Salyka Sengsayadeth, ASPET Fellowship, 2001

Dr. Alexis Dagnino Subiabre, University of Chile, Santiago, Chile; Visiting student, 2002.

Dr. Przemyslaw Nowak, Department of Pharmacology, Medical University of Silesia, Poland.

Visiting Scientist: 1999; 2002; 2003; 2006; 2008

Dr. Roseanna Kostrzewa, ASPET Fellowship, 2003

UNIVERSITY COMMITTEES

Faculty Senate, ETSU, 1978-81; Faculty Senate Research Committee, ETSU, 1978-80

Faculty Senate ad hoc Committee on Curriculum, 1979

University Research Development Committee, 1978-85; Chairman, 1982-83

Institutional Self-Study Committee for the ETSU=s Quillen-Dishner College of Medicine 1980-81; Chairman,

Committee on Animal Care Facility, 1980-81

Research Committee on Institutional Self Study for ETSU, 1981-82; 1987-88

Search Committee for Director of Contracts and Grants, 1983

ETSU College of Medicine Student Promotions Committee, 1984-87; 1995-97; 2004-2006, 2008

ETSU Col. Medicine Faculty Advisory Council, 1986-92; 1998-2003; Chairman, 1987-88

Search Committee, Vice-President for Finance & Administration, 1988

Faculty Council ad hoc Committee on Grade Appeal, 1987; Chairman

Organizer of Faculty Forum at ETSU College of Medicine, 1987

Chairman, ETSU College of Medicine Faculty Forums (1988, 1989)

Ad hoc member, Search Committee for Director, Continuing Medical Education, 1990

Chairman, Research Forum Committee, 1990-91

Continuing Medical Education Committee, 1994-96

Graduate Program Review Committee, 1994-96

Graduate Coordinator, Department of Pharmacology (1994-2003)

Ad hoc Tenure Review Committee, 1997

Biomedical Sciences Graduate Committee, 2000-2003

Search Committee, Chairperson, Department of Pharmacology, ETSU College of Medicine, 2005

ETSU Col Medicine, Faculty Promotion and Tenure Committee, 2011- present


JOURNAL AND BOOK EDITORIAL ACTIVITIES 1998 Founding Editor of the journal Neurotoxicity Research

1998-2017, Editor-in-Chief, Neurotoxicity Research. Impact Factor, 3.514 for 2011 (most recent yr) 2010 IF=3.014; 2009 IF=2.439; 2008 IF=2.828; 2007 IF=5.234

2003- present, Editorial Board, J. Neural Transmission

2012- present, Editorial Board, Neurochemical Research

2012-present, Editorial Board, Applied Cell Biology

1998- 2009, Editorial Board, Neurobiology Section of Amino Acids

2002, Guest co-Editor of Neurobiology issue of Amino Acids

1997 - 2001, Editorial Advisory Board, Nutritional Neuroscience

1980 - 2001, Associate Editor, Peptides

2010 – present, Editor-in-Chief, Handbook of Neurotoxicity, Springer Science, New York.

2010 - co-Editor-in-Chief (with Trevor Archer, Gőteborg Univ., Sweden), Springer Science Book series

on Current Topics in Neurotoxicity. Springer Science, New York.

1999 - 2003, Editor-in-Chief, FP Graham Biomedical Book Series

1996 - 1998, Editor-in-Chief, Sulzburger & Graham Biomedical Book Series

HONORS/AWARDS

2005 Doctor Honoris causa, Medical University of Silesia, Katowice, Poland.

2004, 2005 Gender Equity Award, Quillen College of Medicine, East Tennessee State Univ.

2001 Honorary Membership, Polish Pharmacological Society

1997-2003 Visiting Professorship, Medical University of Silesia, Zabrze, Poland

1996, 1999, 2000 Ad hoc reviewer, Grant Agency of Czech Republic Ministry of Health

1994, 1998 Dean’s Teaching Recognition Award

1996 Fellow of the Japan Society for the Promotion of Science

1994 Designation of the Pharmacological Reviews article, "Pharmacological Actions of 6-Hydroxydopamine"

(R.M. Kostrzewa and D.M. Jacobowitz) among the 400 most-cited articles in the life sciences

1993 Designation of the Pharmacol. Reviews article as a Citation Classic in Current Contents

1992 Fellow of the John E. Fogarty International Center

1990 Fellow of the John E. Fogarty International Center

1987 Invited Lecturer, 15th Intl Summer School of Brain Research, Amsterdam, The Netherlands

1981 Recipient, East Tennessee State University Foundation Research Award

GRANT REVIEWS, SITE TEAMS

1994 Site-team reviewer for NIMH at UCLA

2003 Site-team reviewer, Instituto de Ciencies Biomedica Facultad de Medicine, Universidad de

Chile in Santiago, Chile.

2008/July, External Reviewer for the Atlantic Canada Opportunities Agency (ACOA)

Atlantic Innovation Fund (AIF) Project

2010/Nov Review of a TEAM program grant application for the Fundacja na rzecz Nauki Polskiej

(i.e., Foundation for Polish Science).

Ad hoc JOURNAL REVIEWER, 2000- , >100 papers:

Amino Acids Comp. Biochem. Physiol. Neurochem. Res. Peptides

Brain Eur. J. Pharmacol. Neurosci. Lett. Pharmacological Reports

Brain Res. Eur. J. Neurosci. Neurotoxicity Res. Pol. J. Pharmacol.

Neuropharmacology Prog. NeuroPsychopharm. Biol Psychiatry


GRANTS

Kostrzewa, R.M., Growth and Development of Monoaminergic Neurons, R01 NS 14797 NEUA,

06-01-75 to 12-31-78.

Kostrzewa, R.M., Adrenergic-Cholinergic Interactions in the Myocardium, Louisiana Heart

Association, 07-01-75 to 06-30-76.

Kostrzewa, R.M. and M.G. Levitzky, Paralytic Salivary Secretion and the Influence of Circulating

Catecholamines and Exogenous Sympathomimetic Amines, Louisiana State University School of

Dentistry, 07-01-76 to 06-30-77.

Kostrzewa, R.M., Determination of the Mechanisms of Anti-Parkinsonian Activity of L-prolyl-L-

leucyl-glycinamide, American Parkinson's Disease Association, 02-01-77 to 12-31-78.

Kostrzewa, R.M., Association of Neuronal Development with Regenerative Sprouting, National

Foundation March of Dimes, 07-01-77 to 06-30-79.

Kostrzewa, R.M., Sponsor for NIH Research Fellowship to M.B. Clark on Neuronal Development,

Regeneration and Sprouting, 07-01-77 to 06-30-79.

Kostrzewa, R.M., Growth and Development of Monoaminergic Neurons, R01 NS 14797 NEUA

(Supplement), 07-01-78 to 12-31-78.

Kostrzewa, R.M., Investigation of the Altered Mechanisms of Huntington's Chorea: A New

Approach Toward Treatment, East Tennessee State University Research Development Committee

Award, 07-01-78 to 06-30-79.

Kostrzewa, R.M., Growth and Development of Monoaminergic Neurons (Renewal), R01 NS 14797

NEUA (1A)ND, 07-01-78 to 06-30-82.

Kostrzewa, R.M., Influence of Purkinje Cells on Noradrenergic Neuronal Growth, NIH Biomedical

Research Support Grant, 07-01-80 to 03-31-81.

Kostrzewa, R.M., Highly Selective Neurotoxic Agents, 1 R01 NS 16887 NEUB (1A)ND,

Subcontractor with C.L. Blank of the University of Oklahoma, 07-01-81 to 06-30-85.

Kostrzewa, R.M., Topographical Changes in Noradrenergic Fibers Following Regenerative

Sprouting, ETSU Presidential Grant and Research Development Committee Award, 1984.

Kostrzewa, R.M., Description and Mapping of Dopaminergic Fibers to the Pyriform Cortex, East

Tennessee State University Research Development Committee Award, 01-01-85 to 06-30-86.

Kostrzewa, R.M., Peptide Modulation of Dopamine Receptors, East Tennessee State University

Research Development Committee Award, 01-01-87 to 12-31-87.

Kostrzewa, R.M., Neuropeptide Influence on Dopamine Receptor Populations, East Tennessee State


University Presidential Grant, 1987.

Kostrzewa, R.M., Dopamine Receptor Coupling with Second Messenger Production, NIH

Biomedical Research Support Grant, 07-01-88 to 03-31-89.

Kostrzewa, R.M., Dopamine D1 and D2 Receptor Complex in Ontogenetically Altered Animal

Models, Scottish Rite Schizophrenia Research Program, 09-01-89 to 08-31-92.

Kostrzewa, R.M., Association of Behaviors with Dopamine Receptor Status in Animals with

Long-Term Changes in Dopamine D1 and D2 Receptors, Southern Regional Education Board, 1989.

Kostrzewa, R.M., Observation and Testing of Equipment to Digitize Oral Behavior, East Tennessee

State University Presidential Grant, 1990.

Kostrzewa, R.M., Dopamine Agonist-Induction of Stereotypic Behavior in Rats with Supersensitive

D1 and D2 Receptors, John E. Fogarty International Center for Advanced Study in the Health

Sciences, 1990.

Kostrzewa, R.M., Pharmacologic Study on Models of Tardive Dyskinesia, National Institute of

Neurological Disorders and Stroke, NS29505, 1991-95.

Kostrzewa, R.M., Characterization of Supersensitized Serotonin Receptors, East Tennessee State

University Research Development Committee, 1991.

Kostrzewa, R.M., Fellowship Award from the American Society for Pharmacology and Experimental

Therapeutics for sponsoring a summer research fellow, 1992.

Kostrzewa, R.M., Influence of Supersensitized Dopamine D1 and D2 Receptors on in vivo Dopamine

Turnover, John E. Fogarty International Center for Advanced Study in the Health Sciences, 1992.

Kostrzewa, R.M., Autoradiographic localization of 5-HT uptake sites in rat brain: relation to

dopamine receptors supersensitivity, ETSU Grant-in-Aid, 1993.

Kostrzewa, R.M., Use of specialized equipment and conduct of a pilot study on in vivo

microdialysis. Laboratory of R.W. Fuller and K.W. Perry at Eli Lilly Co. East Tennessee State

University Presidential Grant, 1993.

Kostrzewa, R.M., Association of dopamine D1 receptor supersensitivity with changes in the

expression of serotonin receptor mRNAs, NIH Biomedical Research Support Grant, 1994.

Kostrzewa, R.M., Neural involvement and interactions in dyskinetic motor patterns, Japan Society

for the Promotion of Science (JSPS)/Fogarty International Center, Research/Scholar Exchange

Grant, 1996.

Kostrzewa, R.M., Serotonin innervation and effects in coloboma hyperactive mice, ETSU Grant-in-

Aid, 1997-98.


Breese, G.R. and R.M. Kostrzewa (Co-PI), Potential alleviation of oral dyskinesias by olanzepine in

an animal model of tardive dyskinesia. Eli Lilly Co., 1999-01.

Kostrzewa, R.M., Dopamine nerves suppress •OH formation in neostriatum. NINDS 1R15 NS

39272, 1999-2003.

Brown RD and Kostrzewa RM (Co-I), Eli Lilly study on olanzapine effect on impaired memory in

dopamine agonist-primed rats; 2003-04.

Brown RD and Kostrzewa RM (Co-I, 5%), Amphetamine sensitization in a model of

schizophrenia, NINDS, 1 R15 DA020481-01 2006-09.

Kostrzewa RM, ETSU Presidential Grant, Sept-Oct 2009. Project initiation with Prof. Rosario

Moratalla, Cajal Institute, Madrid, Spain.

Kostrzewa RM and R Brown, Preclinical Testing in an Animal Model of ADHD, Merz

Pharmaceutical Co., Frankfurt Germany, 2011-12.

Brown RD (PI) Nicotine and the roles of nicotinic receptors in a rodent model of schizophrenia.

NIH R15 grant application. Kostrzewa RM, collaborator.

Kostrzewa RM, Brown RW. Adolescent methylphenidate in rats: sex differences and brain

plasticity. NIH R15 grant application (submitted June 2012).


SYMPOSIA/CONFERENCES

15

th International Summer School of Brain Research. Conference on Biochemical Basis of Functional

Neuroteratology. Invited Lecture: Neurochemistry of Functional Neuroteratology of Catecholaminergic Neurons.

Amsterdam, The Netherlands, 1987.

Organizer, symposium on The Basal Ganglia in Health and Disease: Perspectives on Future Treatment of

Parkinsonism, Psychosis and Tardive Dyskinesia. Lecture: Prolyl-leucyl-glycinamide Attenuation of Neuroleptic-

Iinduced Impairment of Dopamine D1 and D2 Receptor Ontogeny: Implication for Treatment of Tardive Dyskinesia.

Sponsor: Sandoz Pharmaceutical Co. East Tennessee State University, Johnson City, TN 1988.

Proceedings of the Society for Experimental Biology and Medicine, Southeastern Meeting. Lecture: Dopamine

Agonists Modify the Development of Dopamine D1 and D2 Receptor Responsiveness. Johnson City, TN, 1989.

11th Annual Meeting of the Southeastern Pharmacology Society. Organizer of the symposium Neural Adaptations to

Drugs of Abuse. Sponsors: Burroughs Wellcome Company, Upjohn Pharmaceutical Company, East Tennessee State

University, Johnson City, TN 1990.

11th Annual Meeting of the Southeastern Pharmacology Society. Organizer of the symposium Vistas for CNS Active

Drugs. Sponsors: Glaxo Pharmaceuticals, Eli Lilly Pharmaceutical Company, Parke-Davis Pharmaceutical Company,

Sandoz Pharmaceuticals; Somerset Pharmaceuticals; East Tennessee State University, 1990.

11th Annual Meeting of the Southeastern Pharmacology Society. Organizer of the Program for Graduate Students:

Careers in Pharmacology. Sponsors: Beecham Pharmaceutical Company, Upjohn Pharmaceutical Company, East

Tennessee State University, Johnson City, TN 1990.

1st International Conference on Botulinum and Tetanus Neurotoxins: Neurotrans-mission and Biomedical

Aspects. Invited Lecture: Altered Sensitivity of Recognition Sites for a Neurotransmitter in the Absence of Changes in

Receptor Binding Parameters: Co-Sensitization of an Alternate System. Madison, WI, 1992.

VII International Symposium on Catecholamines. Invited Lecture: Persistent Changes in the Catecholaminergic

System Following Perinatal Insult. Co-chairman with J.W. Gibb of the symposium, Degeneration, Toxicity, Mechanisms

and Developmental Effects. Amsterdam, The Netherlands, 1992.

1st International Congress of the Polish Neuroscience Society. Invited Lecture: Serotonin Systems Mediate

Dopamine Receptor Supersensitivity. Session on APhysiology and Pharmacology of Neurotransmitters and their

Receptors@. Warsaw, Poland, 1992.

5th European Behavioral Pharmacology Society meeting. Organizer and Chairman of the symposium, Animal models

of tardive dyskinesia. Lecture: Interaction of Serotonin and Dopamine Neurotransmitters in the Genesis of Oral Activity.

Berlin, Germany, 1994.

2nd International Congress of the Polish Neuroscience Society. Co-Chairman with R. Brus of the Symposium,

Neuropharmacology I - Dopaminergic Transmission. Lecture: Sensitization to Dopamine and Serotonin Agonists is Not

Correlated with Alterations in Dopamine and Serotonin Contents of Neostriatum after Neonatal Intrastriatal 6-

Hydroxydopamine Injections in Rats. Cracow, Poland, 1995.

2nd International Congress of the Polish Neuroscience Society. Symposium, Neuropharmacology I - Dopaminergic

Transmission. Lecture: Nitric Oxide and Central Dopamine Receptor Reactivity in Rats. Cracow, Poland, 1995.

12th Congress of the Polish Pharmacology Society. Symposium, Dopamine and Motor Control. Lecture:

Complementarity of Dopamine and Serotonin Neurons in Regulating Motor Activity. Bydgoszcz, Poland, 1995.

5th International Congress on Amino Acids: Satellite meeting on Neurobiology. Organizer and Chairman of the

symposium, Neurotoxicity and Neurotoxic Potential of Amino Acids. Lecture: Destruction of Catecholamine-Containing

Neurons by 6-Hydroxydopa, an Endogenous Amine Oxidase Cofactor. Chalkidiki, Greece, 1997.

3rd International Congress of the Polish Neuroscience Society. Co-Organizer with J.Z. Nowak (Polish Academy of


Sciences in d of the satellite symposium, Dopamine: New Trends in Receptor Research and Therapeutic

Implications. Lecture: Dopamine Receptor Supersensitivity. d, Poland, 1997.

13th

Polish Pharmacology Society Meeting. Co-Organizer with R. Brus (Silesian Academy of Medicine) of the satellite

symposium, Psychopharmacology of Coordinate Dopamine and Serotonin Neurochemistry: New Hypotheses and Impact

on Therapeutic Strategies. Lecture: Interactive Modulatory Roles of Dopamine and Serotonin Neurons on Sensitivity of

the Alternate Neurochemical System. Katowice, Poland, September 1998.

5th

Internet World Congress on Biomedical Sciences (INABIS99). Co-Organizer with J. Smythies (Univ. of San

Diego) of the symposium, Quinones and Other Reactive Oxygen Species in Neurobiologic, Apoptotic and Neurotoxic

Processes. McMaster University, Hamilton, Ontario, Canada, December 1998.

6th

International Congress on Amino Acids: Satellite meeting on Neurobiology. Symposium on Neurobiology of the

Ventral Basal Ganglia Loop. Lecture: Dopaminergic Denervation Enhances Susceptibility to Hydroxyl Radicals in Rat

Neostriatum. Bonn, Germany, August 1999.

4th

Polish International Neuroscience Meeting. Co-Organizer with R. Brus (Silesian Medical University) of the

symposium, New Therapeutic Strategies for Neurologic and Psychiatric Disorders. Lecture: Serotonin Mediates

Amphetamine-Attenuated Hyperlocomotor Activity in Rats. Gdansk, Poland, September 1999.

Fundación Cerebro y Mente International Meeting on Neurotoxicology, Degeneration and Protection in Brain

Disease States. Co-chair with E. Molina-Holgado (Instituto Cajal, Madrid, Spain) of the symposium, Neurotoxicological

Processes in Neuropsychiatry. Mojácar, Spain, October 1999.

Fundación Cerebro y Mente International Meeting on Neurotoxicology, Degeneration and Protection in Brain

Disease States. Co-chair with T. Palomo (Servicio de Psiquiatria, Hospital 12 de Octubre, Madrid, Spain) of the

symposium, The Essence of Protection in Neurodegenerative Disorders. Lecture: Neurotoxicity and Neurodegener-

ation: Among the Shifting Dunes of Protection. Mojácar, Spain, October 1999.

6th

Internet World Congress on Biomedical Sciences (INABIS2000). Co-Organizer with J. Callebert (Rene Descartes

Univ., Paris, France) of the symposium, Reactive Oxygen Species in Neurodegeneration. Presentation: Dopamine

Innervation and L-DOPA Treatment Suppress Hydroxyl Radical Formation in Rat Striatum. Madrid, Spain, February

2000.

Neurotoxicity as a Mechanism for Neurodegenerative Disorders: Basic and Clinical Aspects. Organizing

Committee. Lecture: Neurotoxic and Neuroprotective Properties of Dopamine: Relevance to Parkinson=s Disease.

Pucón, Chile, March 2001.

Neurotoxicity as a Mechanism for Neurodegenerative Disorders: Basic and Clinical Aspects. Chair, Symposium on

Neurotoxic Aspects of Antiparkinsonian Drugs, Pucón, Chile, March 2001.

10th

Neuropsychopharmacological Days. Lecture: Insidious Dopamine: Provocateur or Protectorate in Parkinson=s

Disease? Ustro, Jaszowiec, Poland, May 2001.

7th

International Congress on Amino Acids: Satellite meeting on Neurobiology. Symposium on Neural Mechanisms

Underlying Neurodegenerative Disorders. Lecture: Suppression of Spontaneous Hydroxyl Radical Formation in

Dopamine-Denervated Neostriatum, but Enhancement by Glutamate. Vienna, Austria, August 2001.

14th

Polish Pharmacology Society Meeting. Co-Organizer with Ryszard Brus (Silesian Medical Univ.) of the

symposium, Complimentary Neuroprotective Roles of Dopaminergic and Serotoninergic Neurons. Lecture: Involvement

of Dopaminergic Neurons in Generating and Sequestering Reactive Oxygen Species, Kraków, Poland, September 2001.

Fundación Cerebro y Mente International Meeting on Neurodevelopmental Liabilities in Brain Disease States.

Lecture: The Destructive Propensities of Perinatal Neurotoxins on Brain Development and Function. Mojácar, Spain,

October 2001.

Fundación Cerebro y Mente International Meeting on Neurodevelopmental Liabilities in Brain Disease States.

Chairman, symposium session on Risk Factors Affecting AVulnerability for Movement Disorders. Mojácar, Spain.


11th

Neuropsychopharmacological Days. Lecture: Serotonin and Parkinson’s Disease. Ustron, Jaszowiec, Poland, May

2002.

1st Neurotoxicity Soc. Meeting: Mechanisms for Neurodegenerative Disorders. Lecture: Dopamine Receptor

Supersensitivity as an Index of Neurotoxicity. La Serena, Chile, April 24-27, 2003.

12th

Neuropsychopharmacological Days. Lecture: Priming as a process for producing dopamine D2 receptor

supersensitization: relevance in psychiatric disorders. Ustro, Jaszowiec, Poland, May 2003.

8th

International Congress on Amino Acids: Satellite meeting on Neurobiology. Lecture: L-DOPA elevates dopamine

in Parkinsonian rat striatal tissue and microdialysates without increasing hydroxyl radical production. Rome, Italy,

September 2003.

Fundación Cerebro y Mente International Meeting on Genes and Environment Interplay in Neuropsychiatric

Disorders. Lecture: Dopamine agonist priming in intact and dopamine-lesioned rats: implications for motor

dyskinesias. Mojácar, Spain, October 2003.

XV International Congress of the Polish Pharmacological Society. Co-Organizer with Ryszard Brus (Silesian

Medical Univ.) of the symposium, Neuropsychiatric and Neurodegenerative Disorders – Mechanisms and

Treatment. Lecture: In vivo Microdialysis Studies in an Animal Model of Parkinson’s Disease; Peculiarities of L-

DOPA Therapy, Poznan, Poland, 12-14 September 2004.

Satellite Meeting, Society for Neuroscience. Co-Chairman with J. Segura-Aguilar (Univ. Chile), Symposium on Iron

and Parkinson’s Disease. San Diego, CA, 22 October 2004. Introduction of Symposium by RM Kostrzewa.

2nd Neurotoxicity Soc. Meeting: Mechanisms for Neurodegenerative Disorders. Vice-Chair, Organizing

Committee. Lecture: L-DOPA Effects on Striatal Microdialysate Levels of Hydroxyl Radical in Parkinsonian Rats.

Viña del Mar, Chile, 8-10 April 2005.

14th

Neuropsychopharmacological Days. Member, Scientific Committee. Lecture: Modeling tardive dyskinesia:

predictive new treatment. Ustroń, Jaszowiec, Poland, May 2005.

16th International Congress on Parkinson’s Disease and Related Disorders. Co-Chair with M.B.H. Youdim

(Haifa Univ., Israel) of Symposium on “Controversies on new animal models of Parkinson’s disease: Pro and con.

Berlin, Germany, 5-9 June 2005.

Fundación Cerebro y Mente International Meeting on Implications of Comorbidity for Etiology and

Treatment of Neuropsychiatric Disorders. Lecture: Haloperidol-induced tardive dyskinesia in rats, its persistence

after discontinuation of haloperidol, and effective treatments. Mazagon (Huelva), Spain, October 2005.

Neurotoxicity Society Satellite Meeting, Society for Neuroscience. Organizer and Co-Chairman with J. Segura-

Aguilar (Univ. Chile): Dopamine Oxidation and Parkinson’s Disease. Georgetown University, Washington DC.

November 2005.

15th

Neuropsychopharmacological Days. Member, Organizing Committee. Lecture: Selective neurotoxins and

neuroscience – approaching the golden anniversary. Ustron, Jaszowiec, Poland, May 2006.

European Behavioral Pharmacology Soc. Workshop. Co-Chair with Prof. Ryszard Brus of the Symposium Basic

mechanisms of neurodegeneration and neuroprotection. Krakow, Poland, 02-04 September 2006.

Neurotoxicity Society Satellite Meeting, Society for Neuroscience. Organizer and Co-Chairman with L. Walker

(Emory Univ.): Neurotoxic Mechanisms in Alzheimer’s Disease. Emory University, Yerkes Primate Center, Atlanta,

GA. October 2006.

3rd

Neurotoxicity Society Meeting. Vice-Chair, Organizing Committee. Lecture: Serotonin in a Parkinsonian Rat.

Pucon, Chile, March 2007.


Satellite of 3rd

Neurotoxicity Society Meeting. Organizer, Neurotoxins: Where we’ve been, where we are, where

we’re going. Patagonia, Chile, March 2007.

1st Int’l Congress on ADHD: from Childhood to Adult Disease. Co-Chair with M. Gerlach (Univ. Würzburg) of

the Plenary Session on Experimental Models of ADHD and Plenary Lecturer on Pharmacologic Models of ADHD.

Würzburg, Germany, 2-5 June 2007.

Recent Therapeutic Advances in Parkinson’s and Alzheimer’s Diseases Conference. Lecture: Serotonin and

Parkinson’s Disease; and Chair of the session, Parkinson’s Disease III: Therapeutic Iron Chelators. Technion-Israel

Institute of Technology, Haifa, Israel, 7-10 October 2007.

Fundación Cerebro y Mente International Meeting: ‘Beyond Neuropsychiatric Diagnostics: Symptoms not

Disorders’. Lecture: Dopamine receptor sensitivity and stereotypic / motor behaviours. Mazagon (Huelva), Spain,

18-21 October 2007.

Neurotoxicity Society/UCSD Shiley-Marcos Alzheimer’s Disease Research Center, Satellite Meeting, Society

for Neuroscience. Co-Organizer with J. Segura-Aguilar (Univ. Chile) and Eliezer Maslia (Univ. California in San

Diego): Protein Misfolding and Synaptic Toxicity. Speakers: Z Khachaturian, M Shelanski, DJ Selkow, B Hyman,

JQ Trojanowski, L Mucke, B Ghetti, Z Talloczy, H Ischiropoulos. University of California, San Diego, CA. CME

Accredited thru UCSD. 2 November 2007.

17th

Neuropsychopharmacological Days. Lecture: Advances in Dopamine Research: Success of Three Decades of

Research Collaboration Between the Medical University of Silesia in Poland and the Quillen College of Medicine at

East Tennessee State University in the USA. Ustron, Jaszowiec, Poland, May 2008.

Neurotoxicity Society Satellite Meeting, Society for Neuroscience. Chairman, session on Degeneration and

Neuroprotection of Dopaminergic Neurons. Georgetown University, Washington DC. November 14, 2008.

4th

Neurotoxicity Society Meeting. Vice-Chair, Organizing Committee; Lecture: Amourphous Selective

Neurotoxins; Chairman, Poster session. Arica, Chile, 24-26 April 2009.

Satellite of 4th

Neurotoxicity Society Meeting. Organizing Committee. Debate with Dr. Rosario Moratalla

(Instituto Cajal, Madrid, Spain): Serotonin & Parkinson Disease. Arica, Chile; Tacna, Peru, 27-30 April 2009.

Fundación Cerebro y Mente Intl Meeting: ‘Staging Neuropsychiatric Disorders: Implications for Etiopatho-

genesis & Treatment’. Lecture: Stereotypic Progressions in Psychotic Behaviour. Mojacar Spain, 14-18 Oct 2009.

CME Program on “ADHD: From Basic Science to Bench Side” at 10th

Annual Meeting of the Safety

Pharmacology Society. Lecture: Animal Models of ADHD. Boston, MA, 20-23 September 2010.

4th

Mediterranean Neuroscience Meeting. Co-Chair (with Wael Mohammad, Penn State Univ.) for the symposium

“Attention Deficit Hyperkinetic Disorder (ADHD) from Science to Treatment”, Istanbul, Turkey, Sept. 30-Oct. 3,

2012. [Scheduled in the program] – CANCELLED by RMK & WM

6th

Neurotoxicity Society Meeting. Invited Lecturer: The dopamine D2 agonist quinpirole as a non-

neurodegenerative neurotoxin. Valdivia, Chile, 21-24 March 2013.

XVIII International Congress of the Polish Pharmacological Society. Invited Lecture: “The Changing Face of

Neurotoxins”. Kazimierz Dolny, Poland, 22-25 May 2013.

11th

World Congress of Biological Psychiatry Meeting. Kostrzewa RM. Symposium: Dopamine D2 receptor

supersensitivity: impact on schizophrenia. Co-Chair: R Moratalla (Cajal Inst., Madrid, Spain). RM Kostrzewa

Lecture: Dopamine D2 Receptor Supersensitization – Effect on Dopamine Release and Actions. Other Speakers: R

Maggio (Univ. L’Aquila, Italy), Hiroyuki Nawa (Niigata Univ, Japan), P Sokoloff (Pierre Fabre Research Inst,

Castres, France). Kyoto, Japan. 23-27 June 2013.

11th

International Symposium on VIP, PACAP and Related Peptides. Invited Lecture on “Evolution of Selective

Neurotoxins”, in Neurotoxicity themed session. Pecs, Hungary, 26-31 August 2013.


SCIENTIFIC COMMITTEES

Organizing Committee, 5th

Neurotoxicity Soc. Meeting, Uspallata, Mendoza, Argentina, 2011.

Vice-Chair, Organizing Com., 4th

Neurotoxicity Soc. Meeting, Arica, Chile, Apr. 2009.

Co-Organizer with J Segura-Aguilar (Univ. Chile); Program Chair, Satellite of 4th

Neurotoxicity Soc. Satellite Meeting,

Arica, Chile; Tacna, Peru, April 2009.

Co-Organizer with J Segura-Aguilar (Univ. Chile) and E Masliah (Univ Calif. San Diego) of the Neurotoxicity Society

meeting in San Diego; Symposia on Abnormal Intraneuronal Proteins & Alzheimer Disease, and Abnormal

Intraneuronal Proteins & Parkinson’s Disease, 3 November 2007.

Vice-Chair, Organizing Com., 3rd

Neurotoxicity Soc. Meeting, Pucon, Chile, Mar. 2007.

Vice-Chair, Organizing Com., 3rd

Neurotoxicity Soc. Satellite Meeting, Patagonia, Chile, Mar. 2007.

Co-Organizer with L. Walker of the Neurotoxicity Society meeting at Emory Univ. Yerkes Primate Research Center

in Atlanta; Symposium on Neurotoxic Mechanisms in Alzheimer’s Disease, October 2006.

Member, Scientific Com., Eur. Behav. Pharmacol. Soc. Workshop on Neurodegenerative Disorders, Krakow, Poland,

02-04 September 2006.

Member, Scientific Com., 15th

Neuropsychopharmacological Days, Ustrón, Poland, May 2006.

Co-Organizer with J. Segura-Aguilar of Satellite meeting for the 2005 Society for Neuroscience Meeting in

Washington DC; and symposium on Dopamine Oxidation and Parkinson’s Disease, 11 November 2005.

Member, Program Com., 9th

Intl Congress on Amino Acids, Neurobiology section, Vienna, Austria, August 2005.



Vice-Chair, Organizing Com., 2nd

Neurotoxicity Soc. Meeting, Viña del Mar, Chile, April 2005.

Co-Organizer with J. Segura-Aguilar of Satellite meeting for the 2004 Society for Neuroscience Meeting in San Diego,

CA; and symposium on Iron and Parkinson’s Disease, October 2004.

Member, Scientific Com., 15th Polish Pharmacological Congress, Poznan, Poland, Sept. 2004.


Intl Congress on Amino Acids and Proteins, Rome, Italy, Sept. 2003.

Vice-Chair, Organizing Com., 1st Neurotoxicity Soc. Meeting, La Serena, Chile, Apr. 2003.



Member, Organizing Com., Neurotoxicity Soc. Meeting, Pucon, Chile, March 2001.


Polish Pharmacological Congress, Krakow, Poland, Sept. 2001.


SEMINARS/LECTURES (1990- )

Pharmacologic Modulation of Antipsychotic Actions by an Endogenous Neuropeptide. Department of Environmental

Practice, University of Tennessee School of Veterinary Medicine, Knoxville, TN, 1990.

Dopamine Agonists Sensitize D1 and D2 Receptors During Development. Department of Psychology, UCLA, Los

Angeles, CA, 1990.

Supersensitization of Brain Dopamine Receptors. Department of Pharmacology, Silesian Academy of Medicine,

Katowice, Poland, 1990.

Drug-Induced Alteration of the Development of Brain Dopamine Receptors. Department of Pharmacology, Silesian

Academy of Medicine, Zabrze, Poland, 1990.

Homologous Priming of Brain Dopamine Receptors. Institute of Pharmacological Sciences, Polish Academy of Sciences,

Cracow, Poland, 1990.

Pharmacological Treatment of Parkinsonism. Silesian Academy of Medicine lecture. Research in Medicine Orientation

Program for medical students. Jaszowiec, Poland, 1990.

Primed and Non-Primed Brain Dopamine Receptors. Department of Pharmacology, Lublin Academy of Medicine,

Lublin, Poland, 1990.

Supersensitization of Dopamine D1 Receptors. Department of Pharmacology and Physiology of the Nervous System,

Institute of Psychiatry and Neurology, Warsaw, Poland, 1990.

Production of Homologous and Heterologous Supersensitization of Dopamine Receptors: Models to Study Affective

Disorders. Department of Endocrinology, Louisiana State University School of Medicine, Pennington Biomedical

Research Center, Baton Rouge, LA, 1991.

Neonatal Destruction of Dopamine Neurons Supersensitizes Serotonin Receptors in Rats. Department of Biochemistry,

University of Tennessee, Knoxville, TN, 1992.

Dopamine Receptor Supersensitivity. Department of Pharmacology, Silesian Academy of Medicine, Zabrze, Poland,

1992.

Dopamine-Serotonin Interactions in the Central Nervous System. Department of Pharmacology, Silesian Academy of

Medicine, Zabrze, Poland, 1994.

Supersensitization of Dopamine Receptors is Mediated by Serotonin Neurons. Departments of Psychology and

Pharmacology, and Ohio State University Chapter of the Society for Neuroscience, Columbus, OH, 1995.

Persistent Spontaneous Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Dopamine-Lesioned Rats.

Department of Pharmacology, Silesian Academy of Medicine, Zabrze, Poland, 1995.

Serotonin Nerves Modulate the Motor Regulatory Actions of Dopamine. Department of Pharmacology, College of

Medicine, Howard University, Washington, D.C., 1995.

Dopamine Receptor Sensitivity is Regulated by Serotonin Neurochemistry. Department of Ophthalmology, Yamanashi

Medical University, Tamaho, Yamanashi, Japan, 1996.

Perplexities of Dopamine D2 Receptor Supersensitivity. Department of Pharmacology, Silesian Academy of Medicine,

Zabrze, Poland, 1996.

Role of Reactive Oxygen Species in Neurodegenerative Disorders. Department of Pharmacology, Silesian Academy of

Medicine, Zabrze, Poland, 1997.

Neurotoxicological Actions of 6-Hydroxydopa, an Endogenous Amine Oxidase Cofactor. Katowice Pharmacology

Society, Katowice, Poland, 1997.

Putative Mechanisms Underlying Oral Dyskinesias in an Animal Model of Tardive Dyskinesia. Department of

Chemistry, Virginia Polytechnic University, Blacksburg, VA, 1997.

Proposed Multineuronal Basis for Dopamine Receptor Supersensitivity. Department of Anatomy and Cell Biology, East

Tennessee State University, 1997.

Thirty Years of Highly Selective Neurotoxins: Chemical Tools to Probe the Mind. Department of Pharmacology, Silesian

Medical University, Zabrze, Poland, 1998.

Dopamine Receptor Supersensitivity, a Phenomenon Intricately Linked to Serotonin Receptor Sensitization. Department

of Physiology & Pharmacology, Karolinska Institute, Stockholm, Sweden, 1998.

Amphetamine=s Modulation of Hyperactivity May be Mediated by Serotonin, not Dopamine. Department of

Neurophysiology, Nencki Institute, Warsaw, Poland, 1998.

Duplicitous Dopamine: Pro- and Anti-Oxidant Actions Promote and Protect from Neuronal Necrosis and Apoptosis.

Silesian Medical University, Zabrze, Poland, 1999.

Genesis of Parkinson=s Disease: Apoptosis or Necrosis of Substantia Nigra? Impact on Therapeutic Strategies. Silesian

Medical University Lecture series in Progress in Medicine and Basic Science, Katowice, Poland, 2000.

Serotonin and Parkinson=s Disease. Department of Pharmacology, Medical University of Silesia, Zabrze, Poland, May

2002.


Parkinson=s Disease. Medical student class, Medical University of Silesia, Zabrze, Poland, May 2002; 2003.

Neural Adaptations underlying L-DOPA Treatment in an Animal Model of Parkinson’s Disease. Department of

Pathology, Case Western Reserve University, Cleveland, OH, June 2004. Neural Adaptations underlying L-DOPA Treatment in an Animal Model of Parkinson’s Disease. Department of Internal

Medicine, East Tennessee State University, Nov 2004.

Peculiarities of L-DOPA Therapy of Parkinson’s Disease. Institute of Physiology, Academy of Sciences of the Czech

Republic, June 2005.

Serotonin Modulation of Dopamine Neurotransmission and Reactivity: Relevance to Parkinson’s Disease. Department

of Pharmacology, East Tennessee State University, Feb 2007.

Serotonin & Parkinson’s Disease. Merck-Serono Pharmaceutical Co., Geneva, Switzerland, October 2009.

Serotonin & Parkinson’s Disease. Department of Oncology and Neuroscience, University of Chieti-Pescara, via del

Vestini, 66100 Chiet. Invitation by Prof. Pio Conti. Date – October 14, 2010.


PUBLICATIONS

1. Haugaard N, NH Lee, R Kostrzewa and ES Haugaard (1968) Effects of a disulfide (Ellman's reagent)

and thiols on oxidative phosphorylation and ion transport by rat liver mitochondria. Biochem.

Pharmacol. 18, 2385-2391.

2. Haugaard N, NH Lee, R Kostrzewa, RS Horn and ES Haugaard (1969) The role of sulfhydryl groups

in oxidative phosphorylation and ion transport by rat liver mitochondria. Biochem. Biophys. Acta.

172, 198-204.

3. Jacobowitz D and R Kostrzewa (1971) Selective action of 6-hydroxydopa on noradrenergic terminals:

Mapping of preterminal axons of the brain. Life Sci. 10, 1329-1341.

Kostrzewa R (1971) A biochemical and histofluorescent investigation of the central and peripheral

effects of 6-hydroxydopa on adrenergic and dopaminergic nerves. Doctoral Dissertation, Dissertation

Abstracts Intl. 32 (No.12), 1971. Advisor: David M Jacobowitz.

4. Kostrzewa R and D Jacobowitz (1972) The effect of 6-hydroxydopa on peripheral adrenergic neurons.

J. Pharmacol. Exp. Ther. 183, 284-297.

5. Kostrzewa R and D Jacobowitz (1973) Acute effects of 6-hydroxydopa on central monoaminergic

neurons. Europ. J. Pharmacol. 21, 70-80.

6. Kostrzewa RM and JW Harper (1974) Effects of 6-hydroxydopa on catecholamine-containing neurons

in brains of newborn rats. Brain Res. 69, 174-181.

7. Kostrzewa RM and DM Jacobowitz (1974) Pharmacological actions of 6-hydroxydopamine.

Pharmacol. Reviews 26, 199-288.

8. Fingerman M, WE Julian, MA Spirtes and RM Kostrzewa (1974) The presence of

5-hydroxytryptamine in the eyestalks and brain of the fiddler crab Uca pugilator, its quantitative

modification by pharmacological agents, and possible role as a neurotransmitter in controlling the

release of red pigment-dispersing hormone. Gen. Comp. Pharmacol. 5, 299-303.

9. Kostrzewa RM (1975) Effects of neonatal 6-hydroxydopa treatment on monamine content of rat brain

and peripheral tissues. Res. Commun. Chem. Pathol. Pharmacol. 11, 567-579.

10. Kostrzewa RM and JW Harper (1975) Comparison of the neonatal effects of 6-hydroxydopa and

6-hydroxydopamine on growth and development of noradrenergic neurons in the central nervous

system, in Chemical Tools in Catecholamine Research (T Malmfors, G Jonsson and C Sachs, Eds),

North Holland, Amsterdam, pp. 181-189.

11. Spirtes MA, RM Kostrzewa and AJ Kastin (1975) Effect of melanocyte stimulating hormone (MSH)

and MSH-release inhibiting factor on levels and synthesis of serotonin in various brain regions of

control and hypophysectomized rats. Pharmacol. Biochem. Behav. 3, 1011-1016.

12. Kostrzewa RM, AJ Kastin and MA Spirtes (1975) Effects of MSH and MIF-I on activity of

catecholamine-containing neurons in rat brain. Pharmacol. Biochem. Behav. 3, 1017-1023.

13. Kastin AJ, NP Plotnikoff, CA Sandman, MA Spirtes, RM Kostrzewa, SM Paul, LO Stratton, LH

Miller, F Labrie, AV Schally and H Goldman (1975) The effects of MSH and MIF on the brain, in

Anat. Neuroendocrinol., WE Stumpf and LD Grant, Eds), Karger, Basel, pp. 290-297.


14. McLean JH, RM Kostrzewa and JG May (1976) Behavioral and biochemical effects of neonatal

treatment of rats with 6-hydroxydopa. Pharmacol. Biochem. Behav. 4, 601-607.

15. Kostrzewa RM and RE Garey (1976) Effects of 6-hydroxydopa on noradrenergic neurons in

developing rat brain. J. Pharmacol. Exp. Ther. 197, 105-118.

16. Klara PM, RM Kostrzewa and KR Brizzee (1976) Destructive action of systemically administered 6-

hydroxydopamine on the rat area postrema. Brain Res. 104, 187-192.

17. Christensen CW, CT Harston, AJ Kastin, RM Kostrzewa and MA Spirtes (1976) Investigation of α-

MSH and MIF-I effects on cyclic AMP levels in rat brain. Pharmacol. Biochem. Behav. 5, Suppl. 1,

117-120.

18. Spirtes MA, NP Plotnikoff, RM Kostrzewa, CT Harston, AJ Kastin and CW Christensen (1976)

Possible association of increased rat behavioral effects and increased striatal dopamine and

norepinephrine levels during the DOPA- potentiation test. Pharmcol. Biochem. Behav. 5, Suppl. 1,

121-124.

19. Kostrzewa RM, MA Spirtes, JW Klara, CW Christensen, AJ Kastin and TH Joh (1976) Effects of

L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons. Pharmacol. Biochem. Behav. 5,

Suppl. 1, 125-127.

20. McLean JH, RM Kostrzewa and JG May (1976) Minimal brain dysfunction: dopamine depletion?

Science 194, 451. [Letter]

21. Kostrzewa RM and RE Garey (1977) Sprouting of noradrenergic terminals in rat cerebellum following

neonatal treatment with 6-hydroxydopa. Brain Res. 124, 385-391.

22. Christensen CW, MA Spirtes, RM Kostrzewa and AJ Kastin (1978) Neuro- pharmacological aspects

of hypothalamic peptides and α-MSH, in Current Studies of Hypothalamic Functions, Vol. 1

Hormones (K Lederis and S Karger, Eds), Basel.

23. Kostrezewa RM, JW Klara, J Robertson and LC Walker (1978) Studies on the mechanism of

sprouting of noradrenergic terminals in rat and mouse cerebellum after neonatal 6-hydroxydopa. Brain

Res. Bull. 3, 525-531.

24. Kostrzewa RM, AJ Kastin and SK Sobrian (1978) Potentiation of apomorphine actions in rats by

L-prolyl-L-leucyl-glycine amide. Pharmacol. Biochem. Behav. 9, 375-378.

25. Kostrzewa RM, MB Clark and H Fukushima (1979) Regenerative sprouting of noradrenergic

terminals in the cerebellum, in Catecholamines: Basic and Clinical Frontiers, (E Usdin, IJ Kopin and

J Barchas, Eds) Pergamon Press, New York, pp. 797-799.

26. Clark MB, JC King and RM Kostrzewa (1979) Loss of nerve cell bodies in caudal locus coeruleus

following treatment of neonates with 6-hydroxydopa. Neurosci. Lett. 13, 331-336.

27. Kastin AJ, RH Ehrensing, DH Coy, AV Schally and RM Kostrzewa (1979) Behavioral effects of brain

peptides, including LH-RH, in Psychoneuroendocrin-ology in Reproduction (L Zichella and P

Pancheri, Eds), Elsevier, North Holland, pp. 69-80.

28. Morgan DN, JH McLean and RM Kostrzewa (1979) Effects of 6-hydroxy-dopamine and

6-hydroxydopa on development of behavior. Pharmacol. Biochem. Behav. 11, 309-312.


29. Kostrzewa RM, J Hardin, RL Snell, AJ Kastin, DH Coy and F Bymaster (1979) MIF-I and

postsynaptic receptor sites for dopamine. Brain Res. Bull. 4, 657-662.

30. Kostrzewa RM, H Fukushima, CT Harston, KW Perry, RW Fuller and AJ Kastin (1979) Striatal

dopamine turnover and MIF-I. Brain Res. Bull. 4, 799-802.

31. Kastin AJ, AV Schally and RM Kostrzewa (1980) Possible aminergic mediation of MSH release and

of the CNS effects of MSH and MIF-I. Fed. Proc. 39, 2931-2936.

32. Harston CT, A Morrow and RM Kostrzewa (1980) Enhancement of sprouting and putative

regeneration of central noradrenergic fibers by morphine. Brain Res. Bull. 5, 421-424.

33. Kostrzewa RM, H Fukushima, A Morrow, P Cohenour, T Hsi, RE Lehr and CL Blank (1980) α-

Methyl-6-aminodopamine: Depletion of catecholamines in mouse brain and peripheral tissues. Life

Sci. 27, 2245-2250.

34. McLean JH, RS Glasser, RM Kostrzewa and JG May (1980) Effects of neonatal 6-hydroxydopa on

behavior in female rats. Pharmacol. Biochem. Behav. 13, 863-868.

35. Kastin AJ, RM Kostrzewa, AV Schally and DH Coy (1980) Neonatal administration of

met-enkephalin facilitates maze performance of adult rats. Pharmacol. Biochem. Behav. 13, 883-886.

36. Walker LC, AA Gerall and RM Kostrzewa (1980) Rostral midbrain lesions and copulatory behavior in

male rats. Physiol. Behav. 26, 349-353.

37. Harston CT, MB Clark, JC Hardin and RM Kostrzewa (1981) Opiate- enhanced toxicity and

noradrenergic sprouting in rats treated with 6-hydroxydopa. Europ. J. Pharmacol. 71, 365-373.

38. Harston CT, MB Clark, JC Hardin and RM Kostrzewa (1982) Developmental localization of

noradrenergic innervation to the rat cerebellum following neonatal 6-hydroxydopa and morphine

treatment. Dev. Neurosci. 5, 252-262.

39. Kostrzewa RM, CT Harston, H Fukushima and R Brus (1982) Noradrenergic fiber sprouting in the

cerebellum. Brain Res. Bull. 9, 509-517.

40. Kostrzewa RM and D Klisans-Fuenmayor (1984) Development of an opioid- specific action of

morphine in modifying recovery of neonatally-damaged noradrenergic fibers in rat brain. Res.

Commun. Chem. Pathol. Pharmacol. 46, 3-11.

41. Klisans-Fuenmayor D, CT Harston and RM Kostrzewa (1986) Alterations in noradrenergic

innervation of the brain following dorsal bundle lesions in neonatal rats. Brain Res. Bull. 16, 47-54.

42. Heydorn WE, KQ Nguyen, GJ Creed, RM Kostrzewa and DM Jacobowitz (1986) Effects of bilateral

lesion of the locus coeruleus and of neonatal administration of 6-hydroxydopamine on the

concentration of individual proteins in rat brain. Brain Res. 367, 31-38.

43. Kostrzewa RM and CT Harston (1986) Altered histofluorescent pattern of noradrenergic innervation

of the cerebellum of the mutant mouse Purkinje cell degeneration. Neuroscience 8, 809-815.

44. Kostrzewa RM, JC Hardin and DM Jacobowitz (1988) Destruction of cells in the midportion of the

locus coeruleus by a dorsal bundle lesion in neonatal rats. Brain Res. 442, 321-328.


45. Kostrzewa RM (1988) Reorganization of noradrenergic neuronal systems following neonatal chemical

and surgical injury. Progr. Brain Res. 78, 405-423.

46. Saleh MI and RM Kostrzewa (1988) Impaired striatal dopamine receptor development: Differential

D-1 regulation in adults. Europ. J. Pharmacol. 154, 305-311.

47. Kostrzewa RM and MI Saleh (1989) Impaired ontogeny of striatal dopamine D1 and D2 binding sites

after postnatal treatment of rats with SCH-23390 and spiroperidol. Dev. Brain Res. 45, 95-101.

48. Saleh MI and RM Kostrzewa (1989) MIF-1 attenuates spiroperidol alteration of striatal dopamine D2

receptor ontogeny. Peptides 10, 35-40.

49. Kostrzewa RM (1989) Neurotoxins that affect central and peripheral catecholamine neurons, in

Neuromethods, vol. 12, Neuropharmacology Section, (AA Boulton, GB Baker and AV Juorio, Eds),

Humana Press, Totowa, NJ, pp. 1-48.

50. Kostrzewa RM, TG White, JE Zadina and AJ Kastin (1989) MIF-1 attenuates apomorphine

stereotypies in adult rats after neonatal 6-hydroxydopamine. Europ. J. Pharmacol. 163, 33-42.

51. Kostrzewa RM and MI Saleh (1989) Attenuation of SCH-23390-induced alteration of striatal

dopamine D-1 receptor ontogeny by prolyl-leucyl- glycinamide in the rat. Neuropharmacol. 28,

805-810.

52. Kostrzewa RM, A Hamdi and FP Kostrzewa (1990) Production of prolonged supersensitization of

dopamine D2 receptors. Europ. J. Pharmacol. 183, 1411-1412.

53. Arbogast LY, JK Neumann, RM Kostrzewa and BW Arbogast (1990) Decreased VLDL preventing

activity in response to a reverse mirror drawing stressor. SAAS Bull. Biochem. and Biotech. 3, 80-84.

54. Kostrzewa RM and A Hamdi (1991) Potentiation of spiroperidol-induced oral activity in rats after

neonatal 6-hydroxydopamine. Pharmacol. Biochem. Behav. 38, 215-218.

55. Neumann JK, DS Chi, BW Arbogast, RM Kostrzewa and LM Harvill (1991) Relationship between

blood groups and behavior patterns in men who have had myocardial infarction. Southern Med. J. 84,

214-218.

56. Kostrzewa RM (1991) Career planning for pharmacologist trainees. The Pharmacologist 33, 41-45.

57. Kostrzewa RM and R Brus (1991) Is dopamine-agonist induced yawning behavior a D3 mediated

event? Pharmacol. Lett. section of Life Sci. 48, PL-129.

58. Kostrzewa RM and R Brus (1991) Ontogenic homologous supersensitization of quinpirole-induced

yawning in rats. Pharmacol. Biochem. Behav. 39, 517-519.

59. Kostrzewa RM and L Gong (1991) Supersensitized D1 receptors mediate enhanced oral activity after

neonatal 6-OHDA. Pharmacol. Biochem. Behav. 39, 677-682.

60. Hamdi A and RM Kostrzewa (1991) Ontogenic homologous supersensitization of dopamine D1

receptors. Europ. J. Pharmacol. 203, 115-120.

61. Gong L, EA Daigneault, RV Acuff and RM Kostrzewa (1991) Vitamin E supplements fail to protect

mice from acute MPTP neurotoxicity. Neuroreport 2, 544-546.


62. Kostrzewa RM, R Brus and J Kalbfleisch (1991) Ontogenetic homologous sensitization to the

antinociceptive action of quinpirole in rats. Europ. J. Pharmacol. 209, 157-161.

63. Gong L and RM Kostrzewa (1992) Supersensitized oral response to a serotonin agonist in neonatal 6-

OHDA treated rats. Pharmacol. Biochem. Behav. 41, 621-623.

64. Gong L, RM Kostrzewa, RW Fuller and KW Perry (1992) Supersensitization of the oral response to

SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J. Pharmacol.

Exp. Ther. 261, 1000-1007.

65. Kostrzewa RM, R Brus, DH Coy, H Criswell, PS Coogan and AJ Kastin (1992) D-Ala2,F5Phe

4-

dynorphin amide, an opiate with analgesic and lethal properties. Pol. J. Pharm. Pharmacol. 44, 109-

120.

66. Chi DS, L Gong, EA Daigneault and RM Kostrzewa (1992) Effects of MPTP and vitamin E

treatments on immune function in mice. Intl. J. Immunopharmacol. 14, 739-746.

67. Kostrzewa RM, L Gong and R Brus (1992) Serotonin (5-HT) systems mediate dopamine (DA)

receptor supersensitivity. Acta Neurobiol. Exp. 53, 31-41.

68. Kostrzewa RM, R Brus, M Rykaczewska and A Plech (1993) Low dose quinpirole ontogenically

sensitizes to quinpirole-induced yawning in rats. Pharmacol. Biochem. Behav. 44, 487-489.

69. Kostrzewa RM and D Neely (1993) Enhanced pilocarpine-induced oral activity responses in neonatal

6-OHDA-treated rats. Pharmacol. Biochem. Behav. 45, 737-740.

70. Kostrzewa RM and AJ Kastin (1993) Tyr-MIF-1 attenuates development of tolerance to spiperone-

induced catalepsy in rats. Brain Res. Bull. 31, 707-712.

71. Kostrzewa RM, J Guo and FP Kostrzewa (1993) Ontogenetic quinpirole treatments induce vertical

jumping activity in rats. Europ. J. Pharmacol. 239, 183-187.

72. Gong L, RM Kostrzewa, R Brus, RW Fuller and KW Perry (1993) Ontogenetic SKF 38393 treatments

sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats. Dev. Brain Res. 76, 59-65.

73. Kostrzewa RM, R Brus, KW Perry and RW Fuller (1993) Age-dependence of a 6-hydroxydopamine

lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev.

Brain Res. 76, 87-93.

74. Gong L, RM Kostrzewa and J Kalbfleisch (1993) MIF-1 fails to modify agonist-induced oral activity

in neonatal 6-OHDA treated rats. Peptides 14, 1159-1164.

75. Kostrzewa RM (1993) Altered sensitivity of recognition sites for catecholamines in the absence of

changes in receptor binding parameters, in Botulinum and Tetanus Neurotoxins: Neurotransmission

and Biomedical Aspects (G DasGupta, Ed), Plenum Press, pp. 521-537.

76. Gong L, RM Kostrzewa, KW Perry and RW Fuller (1993) Dose-related effects of a neonatal 6-OHDA

lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev.

Brain Res. 76, 233-238.

Kostrzewa RM (1993) A Citation Classic: Pharmacology of 6-Hydroxydopamine, in Current

Contents Life Sciences vol. 36 (no. 32), p. 9. For the article by RM Kostrzewa and DM Jacobowitz,

Pharmacol. Reviews 26, 199-288, 1974. [590 citations through 1992].


77. Arbogast BW, JK Newmann, LY Arbogast, SC Leeper and RM Kostrzewa (1994) Transient loss of

serum protective activity following short term stress: a possible chemical link between stress and

atherosclerosis. J. Psychosom. Res. 38, 871-884.

78. Huang N and RM Kostrzewa (1994) Enhanced oral activity response to A77636 in neonatal 6-

hydroxydopamine-lesioned rats. Europ. J. Pharmacol. 253, 163-166.

79. Kostrzewa RM, R Brus, JH Kalbflesich, KW Perry and RW Fuller (1994) Proposed animal model of

attention deficit hyperactivity disorder. Brain Res. Bull. 34, 161-167.

80. Gong L, RM Kostrzewa and C Li (1994) Neonatal 6-OHDA and adult SKF 38393 treatments alter

dopamine D1 receptor mRNA levels: Absence of other neurochemical associations with the enhanced

behavioral responses of lesioned rats. J. Neurochem. 63, 1282-1290.

The 1974 Pharmacol. Reviews article by RM Kostrzewa and DM Jacobowitz, `Pharmacological

Actions of 6-Hydroxydopamine' was ranked by Current Contents among the 400 most-cited articles in

the life sciences.

81. Brus R, RM Kostrzewa, KW Perry and RW Fuller (1994) Supersensitization of the oral response to

SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-

dihydroxytryptamine treatment. J. Pharmacol. Exp. Ther. 268, 231-237.

82. Huang N-Y and RM Kostrzewa (1994) Persistent oral dyskinesias in haloperidol-withdrawn neonatal

6-OHDA-lesioned rats. Europ. J. Pharmacol. 271, 433-437.

83. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci. Biobehav. Reviews 19, 1-17.

84. Brus R, R Kostrzewa, W Felinska, A Plech, R Szkilnik and J Frydrych (1995) Ethanol inhibits

cadmium accumulation in brains of offspring of pregnant rats that consume cadmium. Toxicol. Lett.

76, 57-62.

85. Brus R, A Plech and RM Kostrzewa (1995) Enhanced quinpirole responses in rats lesioned neonatally

with 5,7-dihydroxytryptamine. Pharmacol. Biochem. Behav. 50, 649-653.

86. W Felinska, R Brus, R Szkilnik, M Rykaczewska, A Plech, RM Kostrzewa and J Frydrych (1995)

Cadmium modulates reactivity of central dopamine receptors in rats prenatally exposed to ethanol.

Pol. J. Environ. Studies 4, 31-36.

87. Jedrusiak J, R Brus, RM Kostrzewa and Z Sowinski (1995) Dopaminergic neuronal systems

modulate the central cardiovascular effects of TRH in rats. Pol. J. Pharmacol. 47, 43-52.

88. Brus R, W Felinska, M Rykaczewska, RM Kostrzewa, R Szkilnik and A Plech (1995) Prenatal ethanol

diminishes reactivity of presumed dopamine D3 receptors in rats. Pol. J. Pharmacol. 47, 109-114.

89. Plech A, R Brus, JH Kalbfleisch and RM Kostrzewa (1995) Enhanced oral activity responses to

intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-

lesioned rats. Psychopharmacol. 119, 466-473.

90. Perry KW, RM Kostrzewa and RW Fuller (1995) Persistence of long-lasting serotonin depletion by p-

chloroamphetamine in rat brain after 6-hydroxydopamine lesioning of dopamine neurons. Biochem.

Pharmacol. 50, 1305-1307.

91. Brus R, R Szkilnik, RM Kostrzewa, A Plech, M Rykaczewska, P Nowak and J Shani (1995)

Reactivity of central dopamine receptors after an electric shock in male and female rats. Pharmacol.

Commun. 7, 79-86.


92. Brus R, R Szkilnik, RM Kostrzewa, I Jedrusiak, J Konecki, M Glowacka and J Shani (1995)

Modulation of glucose uptake in rat brain after administration of quinpirole and SKF 38393, two

central dopamine-receptor agonists. Pharmacol. Commun. 7, 87-91.

93. Ma S, L Lin, R Rhagavan, P Cohenour, PYT Lin, J Bennett, RJ Lewis, EL Enwall, R Kostrzewa, RE

Lehr and CL Blank (1995) In vivo and in vitro studies on the neurotoxic potential of 6-

hydroxydopamine analogs. J. Med. Chem. 38, 4087-4097.

94. Brus R, R Szkilnik and RM Kostrzewa (1996) Nitric oxide (NO) and central dopamine (DA) D3

receptor reactivity in rats. Acta Neurobiol.Exp. 56, 15-19.

95. Kostrzewa RM, R Brus, KW Perry and RW Fuller (1996) Dopamine and 5-HT receptor sensitivity

does not correlate with neostriatal dopamine or 5-HT content. Acta Neurobiol. Exp. 56, 21-28.

96. Brus R, RM Kostrzewa, R Szkilnik, W Felinska and A Plech (1996) Prenatal ethanol exposure impairs

dopamine D2 and serotonin agonist effects in rats. Pharmacol. Reviews and Commun. 8, 285-290.

97. Huang N-Y, RM Kostrzewa, C Li, KW Perry and RW Fuller (1997) Persistent spontaneous oral

dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: Absence of

an association with the Bmax for [3H]raclopride binding to neostriatal homogenates. J. Pharmacol. Exp.

Ther. 280, 268-276.

98. Brus R, R Szkilnik and RM Kostrzewa (1997) Quinpirole-induced yawning behavior in rats neonatally

pretreated with 6-hydroxydopamine (6-OHDA) and 5,7-dihydroxytryptamine (5,7-DHT). Med. Sci.

Monitor 3, 324-327.

99. Brus R, R Szkilnik, P Nowak and RM Kostrzewa (1997) Nitro-L-arginine attenuates SKF 38393-

induced oral activity in neonatal 6-hydroxydopamine-lesioned rats. Acta Neurobiol. Exp. 57, 283-287.

100. Brus R, R Szkilnik, I Popieuch, RM Kostrzewa and K Mengel (1997) Effect of aluminum exposure

on central serotonin and muscarine receptor reactivity in rats. Med. Sci. Monitor 3, 631-636.

101. Kostrzewa RM (1998) 6-Hydroxydopa, a catecholamine neurotoxin and endogenous excitotoxin at

non-NMDA receptors, in Highly Selective Neurotoxins: Basic and Clinical Applications (RM

Kostrzewa, Ed), Humana Press, Totowa, NJ, pp. 109-129.

102. Kostrzewa RM (1998) Observations relative to the neurotoxicity and neurotoxic potential of amino

acids. Amino Acids 13, 171-173.

103. Kostrzewa RM and R Brus (1998) Destruction of catecholamine-containing neurons by 6-

hydroxydopa, an endogenous amine oxidase cofactor. Amino Acids 14, 175-179.

104. Kostrzewa RM, TA Reader and L Descarries (1998) Serotonin neural adaptations to ontogenetic

loss of dopamine neurons in rat brain. J. Neurochem. 70, 889-898.

105. Brus R, R Szkilnik, P Nowak, A Kasperska, J Oswiecimska, RM Kostrzewa and J Shani (1998)

Locomotor sensitization of dopamine receptors by their agonists quinpirole and SKF-38393, during

maturation and aging in rats. Pharmacol. Reviews and Commun. 10, 25-30.

106. Brus R, R Szkilnik, P Nowak, R Kostrzewa and J Shani (1998) Sensitivity of central dopamine

receptors in rats to quinpirole and SKF-38393, administered at their early stages of ontogenicity,

evaluated by learning and memorizing a conditioned avoidance reflex. Pharmacol. Reviews and

Commun. 10, 31-36.


107. Brus R, P Nowak, R Szkilnik, RM Kostrzewa and J Shani (1998) Induction of grooming behavior in

male rats by m-chlorophenylpiperazine, a central 5-hydroxytryptamine receptor agonist. Pharmacol.

Reviews and Commun. 10, 37-42.

108. Kostrzewa RM, R Brus and KW Perry (1999) Interactive modulation by dopamine and serotonin

neurons of receptor sensitivity of the alternate neurochemical system. Pol. J. Pharmacol. 5, 39-47.

109. Tizabi Y, RL Copeland Jr, R Brus and RM Kostrzewa (1999) Nicotine blocks quinpirole-induced

behavior in rats: psychiatric implications. Psychopharmacol. 145, 433-441.

110. Kostrzewa RM (1999) Editorial. Neurotoxicity Res. 1, 1-2.

111. Kostrzewa RM (1999) Selective neurotoxins, chemical tools to probe the mind: the first thirty years

and beyond. Neurotoxicity Res. 1, 3-25.

112. Kasperska A, R Brus, R Szkilnik, J Oswiecimska, RM Kostrzewa and J Shani (1999) Modulation of

central dopamine receptor reactivity in the rat, by nitric oxide donors and inhibitor: Behavioral studies.

Pharmacol. Rev. Commun. 10, 311-319.

113. Kasperska A, R Brus, A Sokoa, RM Kostrzewa and J Shani (1999) Sexual differentiation in the

central dopaminergic effect of nitric oxide donors and inhibitor on stereotype behavior changes

induced by amphetamine, but not by apomorphine. Pharmacol. Rev. Commun. 10, 329-339.

114. Kostrzewa RM, JP Kostrzewa and R Brus (2000) Dopaminergic denervation enhances susceptibility to

hydroxyl radicals in rat neostriatum. Amino Acids 19, 183-199.

115a. Kostrzewa RM (2000) Review on apoptosis vs. necrosis of substantia nigra pars compacta in

Parkinson’s disease. Neurotoxicity Res. 2, 239-250.

115b. Kostrzewa RM (2001) Review on apoptosis vs. necrosis of substantia nigra pars compacta in

Parkinson=s disease, in Strategies for Studying Brain Disorders 5: Neurodegenerative Brain

Disorders (T Palomo, T Archer and RJ Beninger, Eds), Fundacion Cerebro y Mente, Madrid, Spain,

Madrid, Spain, pp. 755-768.

116. Oswiecimska J, R Brus, R Szkilnik, P Nowak and RM Kostrzewa (2000) 7-OH-DPAT, unlike

quinpirole, does not prime a yawning response in rats. Pharmacol. Biochem. Behav.67, 11-15.

117. Kostrzewa RM (2000) Crucial role of iron in anesthesia. Commentary in Psycoloquy 11,

issue 032, article 3.

(http://www.cogsci.soton.ac.uk/psyc...article=11.032&submit=View+Article)

118. Beal MF, T Palomo, RM Kostrzewa and T Archer (2000) Neuroprotective and neurorestorative

strategies for neuronal injury. Neurotoxicity Res. 2, 71-84.

119. Archer T, T Palomo and RM Kostrzewa (2001) Neurotoxicity and substance abuse: further fuel for

regulatory dilemma. Neurotoxicity Res. 3, 1-6.

120. Kostrzewa RM (2001) Mechanisms of action of 6-hydroxydopamine, a dopaminergic neurotoxin, in

Mechanisms of Degeneration and Protection of the Dopaminergic System (Segura-Aguilar J, Ed), FP

Graham Publishing Co., New York, NY, pp. 85-104.

121. Palomo T, RJ Beninger, K Jhamandas, RM Kostrzewa, MF Beal and T Archer (2001) Protective and

Restorative Strategies in the Neurodegenerative Disorders, in Neurodegenerative Brain Disorders (T

Palomo, T Archer and RJ Beninger, Eds), Fundacion Cerebro y Mente, Madrid, Spain, pp. 481-500.


122. Nowak P, R Brus and RM Kostrzewa (2001) Amphetamine-induced enhancement of neostriatal in

vivo microdialysate dopamine content in rats, quinpirole-primed as neonates. Pol. J. Pharmacol. 53,

319-329.

123. Oswiecimska J, R Brus, R Szkilnik, A Sokola, RM Kostrzewa and J Shani (2001) Sexual

differentiation in behavioral patterns of rats, pretreated with two central dopamine agonists: quinpirole

and 7-OH-DPAT. Pharmacol. Rev. Commun. 11, 203-213.

124. Kretschmer BD, WJ Schmidt, RM Kostrzewa and M Herrera-Marschitz (2002) Amino acids in

neurobiology: neuroprotective and neurotoxic aspects of amino acids involved in neurotransmission

and neuromodulation. Amino Acids 23, 1-7.

125. Kostrzewa RM, JP Kostrzewa and R Brus (2002) Novel roles of amino acids and analogues in

neurodegenerative disorders. Amino Acids 23, 55-56.

126. Kostrzewa RM, JP Kostrzewa and R Brus (2002) Neuroprotective and neurotoxic roles of levodopa

(L-DOPA) in neurodegenerative disorders relating to Parkinson’s disease. Amino Acids 23, 57-63.

127. Kostrzewa RM and J Segura-Aguilar (2002) Neurotoxicological and neuroprotective elements in

Parkinson=s disease. Neurotoxicity Res. 4, 83-86.

128. Brown RW, JT Gass and RM Kostrzewa (2002) Ontogenetic quinpirole treatments produce spatial

memory deficits and enhance skilled reaching in adult rats. Pharmacol. Biochem. Behav. 72, 591-600.

129. Brus R, P Nowak, A Sokola, RM Kostrzewa and J Shani (2002) Behavioral and biochemical effects of

new central dopamine D3 and D4 receptor antagonists in rats. Pharmacol. Rev. Commun. 12, 39-59.

130. Brus R, P Nowak, A Sokola, L Labus, J Oswiecimska, H. Winiarska, RM Kostrzewa and J Shani

(2002) Exposure of pregnant rats to manganese: effect on levels, turnover and release of biogenic

amines in brains of their offspring. Pharmacol. Rev. Commun. 12, 61-75.

131. Nowak P, R Brus, J Oswiecimska, A Sokola and RM Kostrzewa (2002) 7-Nitroindazole enhances

amphetamine-evoked dopamine release in rat striatum. An in vivo microdialysis and voltammetric

study. J. Physiol. Pharmacol. 53, 251-263.

Palomo T, T Archer, RJ Beninger and RM Kostrzewa (2002) Preface (to special journal edition on

substance abuse). Neurotoxicity Res. 4, iii.

132. Palomo T, T Archer, RJ Beninger and RM Kostrzewa (2002) Neurodevelopmental liabilities of

substance abuse. Neurotoxicity Res. 4, 267-279.

133. Palomo T, RM Kostrzewa, T Archer and RJ Beninger (2002) Neurodevelopmental liabilities in

schizophrenia and affective disorders. Neurotoxicity Res. 4, 397-408.

134. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (2003) Brain sites of movement disorder:

Genetic and environmental agents in neurodevelopmental perturbations. Neurotoxicity Res. 5, 1-26.

135. Kostrzewa RM, JP Kostrzewa and R Brus (2003) Dopamine receptor supersensitivity: an outcome and

index of neurotoxicity. Neurotoxicity Res. 5, 111-118.


136. Brus R, RM Kostrzewa, P Nowak, KW Perry and JP Kostrzewa (2003) Ontogenetic quinpirole

treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-

lesioned rats. Neurotoxicity Res. 5(5), 329-338.

137. Kostrzewa RM and J Segura-Aguilar (2003) Novel mechanisms and approaches in the study of

neurodegeneration and neuroprotection. A review. Neurotoxicity Res. 5(6), 375-384.

138. Brown RW, KD Thompson, KN Thompson, JJ Ward, SK Thacker, ML Williams and RM Kostrzewa

(2004) Nicotine treatment in adulthood alleviates cognitive and skilled reaching impairments in rats

treated during early development with quinpirole: interactions of dopamine D2 receptor sensitivity,

acetylcholine function, and neurotrophic factor expression. Eur. J. Neurosci. 19(6), 1634-1642.

139. Moy SS, A Fernandes, Y Qian, DL Rotella, RM Kostrzewa and GR Breese (2004) Effect of acute

and chronic olanzapine treatment on phencyclidine-induced behavioral sensitization in rats with

neonatal dopamine loss. Pharmacol. Biochem. Behav. 78(1), 47-56.

140. Kostrzewa RM, P Nowak, JP Kostrzewa, RA Kostrzewa and R Brus (2004) Dopamine D2 agonist

priming in intact and dopamine-lesioned rats. Neurotoxicity Res. 6, 457-462.

141. Palomo T, T Archer, RM Kostrzewa and RJ Beninger (2004) Gene-environment interplay in

schizopsychotic disorders. Neurotoxicity Res. 6, 1-9.

142. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (2004) Gene-environment interplay in affect

and dementia: emotional modulation of cognitive expression in personal outcomes. Neurotoxicity Res.

6, 159-173.

143. Sieron A, L Labus, P Nowak, G Cieślar, H Brus, A Durczok, T Zagził, RM Kostrzewa and R Brus

(2004) Alternating extremely low frequency magnetic field increases turnover of dopamine and

serotonin in rat frontal cortex. Bioelectromagnetics 25, 426-430.

144. Brus R, P Nowak, R Szkilnik, U Mikołajun and RM Kostrzewa (2004) Serotoninergics attenuate

hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotoxicity Res.

6, 317-325.

145. Palomo T, RM Kostrzewa, RJ Beninger and T Archer (2004) Gene-environment interplay in

alcoholism and other substance abuse disorders: expressions of heritability and factors influencing

vulnerability. Neurotoxicity Res. 6, 343-361.

146. Palomo T, T Archer, RJ Beninger and RM Kostrzewa (2004) Gene-environment interplay in

neurogenesis and neurodegeneration. Neurotoxicity Res. 6, 415-434. Review.

147. Segura-Aguilar J and RM Kostrzewa (2004) Neurotoxins and neurotoxic species implicated in

neurodegeneration. Neurotoxicity Res. 6, 615-630.

148. Herrera-Marschitz M, BD Kretschmer and RM Kostrzewa (2005) General Introduction: Neurobiology

at the 8th International Congress on Amino Acids and Proteins, Rome, Italy, September 2003. Amino

Acids 28(2), 119-121.

149. Kretschmer BD, RM Kostrzewa and M Herrera-Marschitz (2005) Introduction: Vulnerability of the

CNS to metabolic and drug-related insults. Amino Acids 28(2), 123-125.


150. Durczok A, R Szkilnik, P Nowak, Ł Labus, J Dąbrowska, A Bortel, T Zagził, M Swoboda, W

Rycerski, H Winnicka, RM Kostrzewa and R Brus (2005) Effect of zinc on the central

dopaminergic system of rats prenatally exposed to cadmium. Pol. J. Environ. Studies (in press).

153. Kostrzewa RM, P Nowak, JP Kostrzewa, RA Kostrzewa and R Brus (2005) Peculiarities of L-

DOPA treatment of Parkinson's disease. Amino Acids 28(2), 157-164. Epub 2005 Mar 9.

Kostrzewa RM (2005) Mechanisms for neurodegenerative disorders. IDrugs 8(6), 469-471.

154. Nowak P, RM Kostrzewa, A Kwięcinski, A Bortel, Ł Labus and R Brus (2005) Neurotoxic action

of 6-hydroxydopamine on the nigrostriatal dopaminergic pathway in rats sensitized with D-

amphetamine. J. Physiol. Pharmacol. 56(2), 325-333.

155. Kuballa G, P Nowak, Ł Labus, A Bortel, J Dąbrowska, M Swoboda, A Kwieciński, RM Kostrzewa

and R Brus (2005) Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats.

Comparison with haloperidol and clozapine. Pharmacol. Reports 57, 161-169.

156. Kostrzewa RM, JP Kostrzewa, R Brus, RA Kostrzewa and P Nowak (Sept. 2006) Proposed animal

model of severe Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic

innervation of striatum. J. Neural Transm. [Suppl.] 70, 277-279.

157. Nowak P, Ł Labus, RM Kostrzewa and R Brus (May 2006) DSP-4 prevents dopamine receptor

priming by quinpirole. Pharmacol. Biochem. Behav. 84, 3-7.

158. Nowak P, J Dąbrowska, A Bortel, B Izabela, RM Kostrzewa and R Brus (Nov 2006) Prenatal

cadmium and ethanol increase amphetamine-evoked dopamine release in rat striatum.

Neurotoxicol. Teratol. 28, 563-572.

159. Kostrzewa RM, N-Y Huang, JP Kostrzewa, P Nowak and R Brus (2007) Modeling tardive

dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotoxicity Res. 11(1), 41-50.

160. Nowak P, A Bortel, J Dąbrowska, J Oświęcimska, M Drosik, A Kwieciński, J Opara, RM

Kostrzewa and R Brus (Feb. 2007) Amphetamine and mCPP effects on dopamine and serotonin

striatal in vivo microdialysates in an animal model of hyperactivity. Neurotoxicity Res. 11(2), 131-

144.

161. Nowak P, J Dąbrowska, A Bortel, I Biedka, G Słomian, RM Kostrzewa and R Brus (Dec 2006)

Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-

lesioned rats occurs in an absence of change in microdialysate dopamine levels. Eur. J.

Pharmacol. 552(1-3), 46-54. Epub 2006 Sep 16.

162. Konecki J, G Bielaczyc, P Nowak, R Szkilnik, G Szczerbak, M Swoboda, A Kwieciński, RM

Kostrzewa and R Brus (2006) Effect of pre- and postnatal exposure to zinc on [3H]glucose uptake

in the brain and peripheral tissues of adult rats. Pol. J. Environ. Studies 15, 291-295.

163. Nowak P, T Zagził, J Konecki, G Szczerbak, R Szkilnik, J Niwiński, J Gorzałek, RM Kostrzewa

and R Brus (Oct 2006) Trimetazidine increases [3H]glucose uptake in rat brain. Pharmacol.

Reports 58, 559-561.

164. Nowak P, J Konecki, G Kuballa, R Szkilnik, A Kwieciński, G Szczerbak, M Drosik, J Gorzałek, J

Niwiński, Ł Noras, RM Kostrzewa and R Brus (2006) Effect of the dopamine D3 receptor

antagonist nafadotride on [3H]glucose uptake in the brain and peripheral tissues of rats –


comparison with haloperidol and clozapine. Ann. Acad. Med. Silesia 60 (6), 269-273.

165. Kostrzewa RM (2008) Neurotoxins, In: New Encyclopedia of Neuroscience (Squire L, T Albright,

F Bloom, F Gage and N Spitzer, Eds.) (Elsevier:The Netherlands).

166. Xu X, CC Chua, J Kong, RM Kostrzewa, U Kumaraguru, RC Hamdy and BHL Chua (Dec 2007)

Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent

cell death in HT-22 cells. J. Neurochem.103(5), 2004-2014. Epub 2007 Aug 30.

167. Thacker SK, MK Perna, JJ Ward, TL Schaefer, MT Williams, RM Kostrzewa and RW Brown

(Oct 2006) The effects of adulthood olanzapine treatment on cognitive performance and

neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur. J.

Neurosci. 24(7), 2075-2083.

168. Szczerbak G, P Nowak, RM Kostrzewa and R Brus (Oct. 2007) Maternal lead exposure produces

long-term enhancement of dopaminergic reactivity in rat offspring. Neurochem. Res. 32, 1791-

1798.

Kostrzewa RM (2006) Therapeutic and neuroprotective strategies for neurodegenerative disorders.

Eur. Behav. Pharmacol. Soc. Workshop report. ID Drugs, September 2006.

Kostrzewa RM (2007) Mechanisms for Neurodegenerative disorders. III-Neurotoxicity Society

Meeting in Pucon, Chile. Meeting report. ID Drugs, April 2007.

169. Segura-Aguilar J and RM Kostrzewa (Dec 2006) Neurotoxins and neurotoxicity mechanisms.

Neurotoxicity Res. 10, 263-290.

170. Nowak P, G Szczerbak, I Biedka, M Drosik, RM Kostrzewa and R Brus (2006) Effect of

ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in

Parkinsonian rats. In vivo microdialysis study. J. Physiol. Pharmacol. 57, 583-597.

171. Nowak P, G Szczerbak, J Dąbrowska, A Bortel, I Biedka and RM Kostrzewa (Nov –Dec 2006)

Molecular mechanisms of levodopa action in animal models of Parkinson’s disease. Neurol

Neurochir Pol. (Pol. J. Neurol. Neurosurg.) 40, 517-525.

172. Sieroń A. H Brus, J Konecki, G Cieślar, R Szkilnik, P Nowak, Ł Noras, A Kwieciński, RM

Kostrzewa and R Brus (2007) Pol. J. Environ. Stud. 16, 309-312. Letter to Editor.

173. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (2007) Comorbidity implications in brain

disease: neuronal substrates of symptom profiles. Neurotoxicity Res. 12, 1-15.

174. Palomo T, RM Kostrzewa, RJ Beninger and T Archer (2007) Treatment consideration and

manifest complexity in comorbid neuropsychiatric disorders. Neurotoxicity Res. 12, 43-60.

175. Palomo T, RM Kostrzewa, RJ Beninger and T Archer (2007) Genetic variation and shared

biological susceptibility undrlying comorbidity in neuropsychiatry. Neurotoxicity Res. 12, 29-42.

176. Palomo T, T Archer, RM Kostrzewa and RJ Beninger (2007) Comorbidity of substance abuse with

other psychiatric disorders. Neurotoxicity Res. 12, 17-27.

177. Nowak P, M Swoboda, R Szkilnik, J Konecki, A Kwieciński, J Jośko, Ł Noras, K Sawczuk, RM

Kostrzewa and R Brus (Sep-Oct 2007) Nitric oxide (NO) modulates the amphetamine effect on

[3H]glucose uptake in the brain of rats prenatally exposed to lead. Pharmacol. Reports 59, 601-

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17067304&query_hl=4&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17067304&query_hl=4&itool=pubmed_docsum


605.

178. Kostrzewa RM, JP Kostrzewa, RA Kostrzewa, P Nowak and R Brus (Feb 2008) Pharmacological

models of ADHD. J. Neural Transm. 115, 287-298.

179. Kostrzewa RM (April 2007) The blood-brain barrier for catecholamines – revisited. Neurotox.

Res. 11, 261-271.

180. Kostrzewa RM, L Antkiewicz-Michaluk and F Fornai (2010) Dopaminergic nerves as targets for

neurotoxins, In: Neurotoxicology, Target Organ Toxicity Series, 3rd

Edition (Harry J and H Tilson,

Eds.) (Informa Health Care, New York, NY), pp. 112-137. [ISBN: 9781420054873]

181. Bortel A, D Nitka, L Słomian, P Nowak, E Korossy, R Brus and RM Kostrzewa. Neonatal

noradrenergic lesion with DSP-4 modifies the convulsant effect of bicuculine and

pentylenetetrazole in adult rats. Behavioral and biochemical studies. Ann. Acad. Med. Silesia

62(1), 46-52, 2008.

182. Bortel A, L Słomian, D Nitka, M Świerszcz, M Jaksz, P Nowak, RM Kostrzewa and R Brus (May-

June 2008) Neonatal DSP-4 treatment modifies the vulnerability to phenobarbital and ethanol

evoked sedative-hypnotic effects in adult rats. Pharmacological Reports 60(3), 331-338.

(submitted, September 2007).

183. Paris I, J Lozano, S Cardenas, C Periz-Pastene, K Saud, A Riveros, P Fuentes, P Caviedes, A

Dagnino-Subiabre, R Raisman-Vozari, T Shimahara, JP Kostrzewa, D Chi, RM Kostrzewa, P

Caviedes and J Segura-Aguilar (May/June 2008) The catecholaminergic RCSN-3 cell line: a

model to study dopamine metabolism. Neurotox. Res. 13(3,4), 219-228.

184. Nowak P, G Szczerbak, D Nitka, RM Kostrzewa and R Brus (Apr. 2008) Effect of prenatal lead

exposure on nigrostriatal neurotransmission and hydroxyl radical formation in rat neostriatum:

Dopaminergic-nitrenergic interaction. Toxicology 246, 83-89. Epub 2008 Jan 10.

185. Kostrzewa RM, JP Kostrzewa, R Brown, P Nowak and R Brus (Oct. 2008) Dopamine receptor

supersensitivity: development, mechanisms, presentation, and clinical applicability. Neurotox. Res.

14, 121-128.

186. Kostrzewa RM and J Segura-Aguilar (2007) Botulinum neurotoxin: evolution from poison, to

research tool – onto medicinal therapeutic and future pharmaceutical panacea. Neurotox. Res. 12,

275-290.

187. Kostrzewa RM (Jan 2009) Evolution of neurotoxins: from research modalities to clinical realities,

In Curent. Protocols in Neuroscience, Wiley Interscience. Chapter 1:Unit1.18, pp. 1.18.1-1.18.10.

[in Pub Med].

188. Nowak P, J Jochem, K Zwirska-Korczala, J Josko, L Noras, RM Kostrzewa and R Brus (2008)

Ontogenetic noradrenergic lesion alters histaminergic activity in adult rats. Neurotox. Res. 13, 79-

83.

189. Nowak P, A Bortel, J Dąbrowska, I Biedka, G Slomian, W Roczniak, RM Kostrzewa and R Brus

(May/June 2008) Histamine H3 receptor ligands modulate L-dopa-evoked behavioral responses

and L-dopa-derived extracellular dopamine in dopamine-denervated rat striatum. Neurotox. Res.

13 (3,4), 231-240.

190. Nowak P, Ł Noras, J Jochem, R Szkilnik, H Brus, E Korossy, J Drab, RM Kostrzewa and R Brus


(2009) Histaminergic activity in a rodent model of Parkinson’s disease. Neurotox. Res. 15(2), 246-

251. Neurotox Res. 15(3), 246-251. doi: 10.1007/s12640-009-9025-1. Epub 2009 Feb 28.

191. Nowak P, G Szczerbak, D Nitka, RM Kostrzewa, J Josko and R Brus (Sept-Oct 2008) Cortical

dopaminergic neurotransmission in rats intoxicated with lead during pregnancy. Nitric oxide and

hydroxyl radicals formation involvement. Neurotoxicol Teratol. 30, 428-432. E pub ahead of print,

Mar 2008.

192. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (Aug. 2008) Focusing on symptoms rather

than diagnoses in brain dysfunction: conscious and nonconscious expression in impulsiveness and

decision-making. Neurotox. Res. 14(1), 1-20.

193. Kostrzewa RM, RA Kostrzewa and JP Kostrzewa (March 2009) Botulinum toxin for restoration of

bladder control. The Female Patient 34, 20-23 (submitted Oct. 14, 2008; accepted Nov. 18, 2008).

194. Palomo T, RM Kostrzewa, RJ Beninger and T Archer (Oct. 2008) Schizopsychotic symptom-

profiles and biomarkers: beacons in diagnostic labyrinths. Neurotox. Res. 14(2,3), 79-96.

195. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (Oct. 2008) Affective status in relation to

impulsive, motor and motivational symptoms: personality, development and physical exercise.

Neurotox. Res. 14(2,3), 151-168.

196. Archer T, RM Kostrzewa, RJ Beninger and T Palomo (Oct. 2008) Cognitive symptoms

facilitatory for diagnoses in neuropsychiatric disorders: executive functions and locus of control.

Neurotox. Res. 14(2,3), 205-225.

197. Nowak P, J Oswiecimska, E Korossy, J Drab, A Kwiecinski, J Josko, RM Kostrzewa and R Brus

(2008) Altered functional response of dopamine D3-like receptors in neonatally 6-OHDA-lesioned

rats (rodent model of Parkinson’s disease. Ann. Acad. Med. Silesia 62(3-4), 46-55.

198. Kostrzewa RM (Feb. 2009) Editorial on ‘Neurotoxicity’. Neurotox. Res. 15(1), 1-2. DOI:

10.1007/s12640-009-9029-x.

199. Kostrzewa RM (2010) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist

treatment, In: 5-HT2C Receptors in the Pathophysiology of CNS Disease (Di Giovanni G, E

Esposito, and V Di Matteo, Eds.) (Humana Press/ Springer Science+Business Media, New York),

pp. 383-393. ISBN: 978-1-60761-940-6. DOI: 10.1007/9780-1-60761-941-3.

200. Nowak P, D Nitka, A Kwieciński, J Jośko, J Drab, D Pojda-Wilczek, J Kasperski, RM Kostrzewa

and R Brus (April 2009) Neonatal co-lesion by DSP-4 and 5,7-DHT produces adulthood

behavioral sensitization to dopamine D2 receptor agonists. Pharm. Rep. 61, 311-318.

201. Nowak P, RA Kostrzewa, D Skaba and RM Kostrzewa (April 2010) Acute L-DOPA effect on

hydroxyl radical- and DOPAC-levels in striatal microdialysates of Parkinsonian rats. Neurotox.

Res. DOI: 10.1007/s12640-009-9105-2. online, Sept. 4, 2009. Neurotox. Res. 17(3), 299-304.

207. Archer T and RM Kostrzewa (2010) Staging neurological disorders: expressions of cognitive and

motor disorder. DOI 10.1007/s12640-009-9134-x. [Editorial] online Nov 26, 2009. Neurotox. Res.

18(2), 107-111.

208. Archer T, Kostrzewa RM, Palomo T and Beninger RJ (Nov 2010) Clinical staging in the

pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.


Neurotox Res. 18(3-4):211-228. Epub 2010 Mar 17.

209. Nowak P, Bojanek K, Szkilnik R, Josko J, Boron D, Adwent M, Gorczyca P, Kostrzewa RM, Brus

R (May 2011) Ontogenetic exposure of rats to pre- and post-natal manganese enhances behavioral

impairments produced by perinatal 6-hydroxydopamine. Neurotox Res. 19(4):536-543. Epub 2010

Apr 6. PMID: 20369314. DOI: 10.1007/s126.

210. Archer T, Kostrzewa RM, Beninger RJ, Palomo T (Nov 2010) Staging perspectives in

neurodevelopmental aspects of neuropsychiatry: agents, phases and ages at expression. Neurotox.

Res. 18(3-4):287-305. Epub 2010 Mar 17.

211. Archer T, Beninger RJ, Palomo T, Kostrzewa RM (Nov 2010) Epigenetics and biomarkers in the

staging of neuropsychiatric disorders. Neurotox. Res. 18(3-4):347-366. Epub 2010 Mar 17.

212. Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, Kostrzewa FP, Brus R, Nowak P (Feb 2011)

Stereotypic progressions in psychotic behavior. Neurotox. Res. 19: 243-252. DOI:

10.1007/s12640-010-9192-0

213. Archer T, Kostrzewa RM, Beninger RJ, Palomo T (Feb 2011) Staging neurodegenerative

disorders: structural, regional, biomarker and functional progressions. Neurotox. Res. 19: 211-234.

214. Jośko J, J Drab, P Nowak R Szkilnik, E Kőrőssy, D Boroń, H Brus, RM Kostrzewa, R Brus (July

2011) Thioperamide, an H3 receptor antagonist, prevents [3H]glucose uptake in adult rats lesioned

as neonates with 5,7-dihydroxytryptamine. Neurotox Res. 20(1): 93-96. Epub 2010 Sep 14. PMID:

20838953

215. Jośko J, J Drab, J Jochem, P Nowak, R Szkilnik, E Kőrőssy-Mruk, D Boroń, RM Kostrzewa, H

Brus, R Brus (Aug 2011) Ontogenetic serotoninergic lesioning alters histaminergic activity in rats

in adulthood. Neurotox. Res. 20(2):103-108. Epub 2010 Sep 14. PMID: 20838952. DOI:

10.1007/s12640-010-9217-8.

216. Archer T, A Fredriksson, E Szhulz, RM Kostrzewa (July 2011) Influence of physical exercise on

neuroimmunological functioning and health: aging and stress. Neurotox Res. 20(1):69-83. Epub

2010 Oct 15. DOI: 10.1007/s12640.010-9224-9. PMID: 20953749.

217. Brus R, J Jochem, P Nowak, M Adwent, D Boroń, H Brus, RM Kostrzewa (Feb 2012) Effect of

pre- and postnatal manganese exposure on brain histamine content in a rodent model of

Parkinson’s disease. Neurotox. Res. 21(2):143-148. Epub 2011 Aug 6. PMID: 21822760.

218. Archer T, Kostrzewa RM (Feb 2012) Physical exercise alleviates ADHD symptoms: regional

deficits and development trajectory. Neurotox Res. 21(2):195-209. Epub 2011 Aug 18. [Epub

ahead of print] PMID: 21850535.

219. Ferdyn-Drosik M, P Nowak, K Bojanek, M Bałasz, J Kasperski, D Skaba, R Muchacki, RM

Kostrzewa (Jul-Aug 2010) Neonatal DSP-4 treatment impairs 5-HT1B receptor reactivity in adult

rats. Behavioral and biochemical studies. Pharmacol. Rep. 62(4):608-20. PMID: 20885001.

220. Kostrzewa RM, FP Kostrzewa (Feb 2012) Neonatal 6-hydroxydopamine lesioning enhances

quinpirole-induced vertical jumping in rats that were quinpirole-primed during postnatal ontogeny.

DOI: 10.1007/s12640-011-9268-5. Neurotox Res. 21(2):231-235. Epub 2011 Aug 19. PMID:

21853388.

221. Korossy-Mruk E, Kuter K, Nowak P, Szkilnik R, Kostrzewa RM, Brus R (Jan 2013) Neonatal


DSP-4 treatment modifies analgesic effect of methanandamide, a CB1 receptor agonist in adult

rats. Neurotox Res 23(1), 39–48. (in press, 28 March 2012).

222. Labus L, Nowak P, Szkilnik R, Kostrzewa RM, Boroń D, Brus R (2012) Neonatal DSP-4

lesioning of central noradrenergic neurons: a model for the study of interaction with other

neurotransmitter systems in the brain of adult rats. Annales Acad. Med. Silesiensis (in press).

223. Brown RW, Maple AM, Perna MK, Sheppard AB, Cope ZA, Kostrzewa, RM (2012)

Schizophrenia and substance abuse comorbidity: Nicotine addiction and the neonatal quinpirole

model. Dev Neurosci. 34(2-3), 140-151. Epub 2012 Jul 6. Review.

224. Kostrzewa RM, Kostrzewa JP, Brus R (2014) Tardive dyskinesia: Outcome of antipsychotic

treatment and brain damage? In Section on Diseases and Disorders Relevant to Neurotoxins, in

Handbook of Neurotoxicity (Kostrzewa RM, Editor), Springer New York, pp 2315-2326. ISBN 978-

1-4614-5835-7 (print); ISBN 978-1-4614-5836-4 (eBook); ISBN 978-1-4614-7458-6 (print and

electronic bundle). DOI 10.1007/978-1-4614-5836-4_163.

225. Kostrzewa RM (2014) Survey of Selective Neurotoxins (chapter title), in Section on Selective

Neurotoxins, in Handbook of Neurotoxicity (Kostrzewa RM, Editor), Springer New York, Heidelberg,

Dordrecht, London, 2014, pp 3-67. ISBN 978-1-4614-5835-7 (print); ISBN 978-1-4614-5836-4 (eBook);

ISBN 978-1-4614-7458-6 (print and electronic bundle). DOI 10.1007/978-1-4614-5836-4_53.

226. Archer T, Kostrzewa RM (Jan 2013) The inductive agency of stress: from perinatal to

adolescent induction, In: Laviola G, Macri S: Adaptive and Maladaptive Aspects of

Developmental Stress. Springer New York, pp 1-20. Galley proof, Nov. 12, 2012.

227. Archer T, Ricci S, Rapp-Ricciardi M, Kostrzewa RM (2013) “Polluting agents in Parkinsonism: I

Transition metals”. In Handbook of Neurotoxicity (Kostrzewa RM, Editor) (Springer, New York

NY), Section on Neurotoxicity in Psychiatric and Neurologic Disorders (T Archer and U Sailer,

Section Editors). Submitted September 2012.

228. Chen J, RM Kostrzewa, X Xu (Jan 2014) Necroptosis, a potential therapeutic target for

neurological disorders”. In Handbook of Neurotoxicity (Kostrzewa RM, Editor) (Springer, New York

NY), Section on Selective Neurotoxins (RM Kostrzewa, Section Editor), pp 69-93. . DOI

10.1007/978-1-4614-5836-4_166.

229. Nowak P, Kowalińska-Kania M, Nowak D, Kostrzewa RM, Malinowska-Borowska J (Aug 2013)

Antinociceptive effects of H3 (R-methylhistamine) and GABAB (baclofen) -receptor ligands in an

orofacial model of pain in rats. Neurotox Res 24, 258-264. Epub 2013 Mar 6. Doi: 10.1007/s12640-

013-9385-4. PMID: 23463522.

230. Kostrzewa JP, RM Kostrzewa (2014?) p-Chloroamphetamine potentiated dopamine release into in

vivo microdialysates of partially serotonin-denervated neostriatum in an animal model of Parkinson’s

disease: implications for treatment of Parkinson’s disease. Neurochem Res. (to be submitted, Nov

2013).

231. Szkilnik R, R Brus, J Malinowska-Borowska, D Nowak, M Waliczek, RM Kostrzewa, P Nowak

(2014) Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral

responses of rats to dopamine D1 and D2 agonist treatments. Environ. Toxicol. Pharmacol. 37, 28-36.

232. Chandley MJ, A Szebeni, K Szebeni, JD Crawford, CA Stockmeier, G Turecki, RM Kostrzewa,

GA Ordway (submitted Oct 2013) Elevated gene expression of glutamate receptors in noradrenergic


neurons from the locus coeruleus in major depression. Int J Neuropsychopharmacol (under review).

233. Bałasz M, R Szkilnik, R Brus, J Malinowska-Borowska, D Nowak, RM Kostrzewa, P Nowak

(2014?) Perinatal manganese exposure and hydroxyl radical formation in rat brain. In preparation.


BOOKS

Kostrzewa RM (Author) Pharmacology, Blond’s Medical Guides, 398 pages, Sulzburger & Graham

Publishers, New York, N.Y. 1996. ISBN 0-945819-48-X

Kostrzewa RM (Editor) Highly Selective Neurotoxins: Basic and Clinical Applications, 404 pages, The

Humana Press, Totowa, N.J., 1998. ISBN 0-89603-465-8

Beninger RJ, T Palomo, RM Kostrzewa and T Archer (co-Editors), 762 pages, Neurodevelopmental

Liabilities in Brain Disease States, 762 pages, Fundación Cerebro y Mente, Madrid, Spain, 2003.

ISBN 84-921848-9-2

Palomo T, RJ Beninger, RM Kostrzewa and T Archer (co-Editors) Gene-Environment I-nterplay in Brain

Disease States, 575 pages, Fundación Cerebro y Mente, Madrid, Spain, 2005. ISBN 84-934250-1-X

Palomo T, RJ Beninger, RM Kostrzewa and T Archer (co-Editors), 698 pages, Implications of

Comorbidity for Etiology and Treatment of Neuropsychistric Disorders, Fundación Cerebro y Mente,

Madrid, Spain, 2007. ISBN 978-84-934250-0-5

Palomo T, RJ Beninger, RM Kostrzewa and T Archer (co-Editors), 708 pages, Beyond Neuropsychiatric

Diagnostics: Symptoms not Disorders, Fundación Cerebro y Mente, Madrid, Spain, 2009. ISBN 978-

84-934250-4-3

Palomo T, RM Kostrzewa and RJ Beninger (co-Editors), 433 pages, Staging Neuropsychiatric Disorders:

Implications for Etiopathogenesis and Treatment, Fundación Cerebro y Mente, Madrid, Spain, 2013.

ISBN 978-1-4614-7263-6

Kostrzewa RM (Editor-in-Chief) Handbook of Neurotoxicity, Springer New York, Heidelberg, Dordrecht,

London, 2014. ISBN 978-1-4614-5835-7 (print); ISBN 978-1-4614-5836-4 (eBook); ISBN 978-1-

4614-7458-6 (print and electronic bundle). DOI 10.1007/978-1-4614-5836-4

Kostrzewa RM (Editor) The Process of Dopamine Receptor Supersensitivity, in the “The Receptor Series”

http://www.springer.com/series/7668 (Series Editor: G Di Giovanni, Univ Malta), Springer: Vienna.

Proposal submitted.

http://www.springer.com/series/7668


ABSTRACTS AND PRESENTATIONS

Jacobowitz D and RM Kostrzewa (1971) The effect of 6-hydroxydopa on central and peripheral adrenergic neurons.

Satellite Symposium, Intl. Congress of Physiol. Soc., Warsaw, Poland.

Jacobowitz D and RM Kostrzewa (1971) The effect of 6-hydroxydopa on brain monoaminergic neurons. 22nd

Am.

Soc. Pharmacology & Exp. Ther. meeting, Burlington, VT.

Kostrzewa RM and D Jacobowitz (1971) The effect of 6-hydroxydopa on peripheral adrenergic neurons. 22nd

Am.

Soc. Pharmacology & Exp. Ther. meeting, Burlington, VT.

Teitelbaum P, E Satinoff, J Marshall, RM Kostrzewa and D Jacobowitz (1971) Disturbances in the regulation of

body temperature and food intake in rats caused by 6-hydroxydopa. 22nd

Am. Soc. Pharmacology & Exp. Ther.

meeting, Burlington, VT.

Kostrzewa RM (1972) Studies on the mechanism of action of 6-hydroxydopa. 56th

Federation Am. Soc. Exp. Biol.

Meeting, Atlantic City, NJ.

Kostrzewa RM and JW Harper (1973) Effects of 6-hydroxydopa on central monoaminergic neurons in newborn

rats. 57th

Federation Am. Soc. Exp. Biol. Meeting, Atlantic City, NJ.

Kostrzewa RM (1974) Impaired development of noradrenergic neurons by 6-hydroxy-dopa in rat central nervous

system. 58th

Federation Am. Soc. Exp. Biol. Meeting, Atlantic City, NJ.

McLean JH, RM Kostrzewa and JG May (1974) Behavioral and biochemical effects of early injections of

6-hydroxydopa. 20th

Southeastern Psychological Assn. Meeting, El Paso, TX.

Kastin AJ, NP Plotnikoff, CA Sandman, MA Spirtes, RM Kostrzewa, SM Paul, LO Stratton, LH Miller, F Labrie,

AV Schally and H Goldman (1974) The effects of MSH and MIF on the brain. Intl. Conference on the

Neurobiology of CNS-Hormone Interactions, Chapel Hill, NC.

Kostrzewa RM, MA Spirtes and AJ Kastin (1974) Effects of melanocyte stimulating hormone (MSH) and

MSH-release inhibitory factor (MIF) on functional activity of central catecholamine-containing neurons. 25th

Am.

Soc. Pharmacology & Exp. Ther. Meeting, New Orleans, LA.

Spirtes MA, RM Kostrzewa and AJ Kastin (1974) Effects of melanocyte stimulating hormone (MSH) and

MSH-release inhibitory factor (MIF) on serotonin content and turnover in rat brain. 25th

Am. Soc. Pharmacology &

Exp. Ther. Meeting, New Orleans, LA.

Kostrzewa RM and JW Harper (1975) Comparison of the neonatal effects of 6- hydroxydopa and

6-hydroxydopamine on growth and development of noradrenergic neurons in the central nervous system. Intl.

Symposium on Chemical Tools in Catecholamine Research, Goteborg, Sweden.

Kostrzewa RM (1975) Age-related alterations in norepinephrine content by 6- hydroxydopa in regions of rat brain

receiving projections from the locus coeruleus. 6th

Intl Union of Pharmacology, Helsinki, Finland.

Spirtes MA, AJ Kastin and RM Kostrzewa (1975) Effects of melanocyte stimulating hormone (MSH) and

MSH-release inhibitory factor on serotonin turnover in hypophysectomized rats. 6th

Intl Union of Pharmacology,

Helsinki, Finland.

Spirtes MA, RM Kostrzewa, NP Plotnikoff and AJ Kastin (1975) Significant increases in dopamine and

norepinephrine levels after prolyl-leucyl-glycinamide in rats subjected to the behavioral dopa potentiation test. 5th

Soc. Neuroscience meeting, New York, NY.

Sweig R, JH McLean, RM Kostrzewa and JG May (1975) Behavioral and biochemical effects of neonatal

6-hydroxydopa. 5th


Kostrzewa RM and RE Garey (1975) Investigation of the development of cerebellar noradrenegic neurons after

6-hydroxydopa. 5th


Musgrave JB, JG May, R Sweig, JH McLean and RM Kostrzewa (1976) The effects of neonatal injections of

6-hydroxydopa on the habituation of a startle response in rats. 22nd

Southeastern Psychological Assn. meeting, New

Orleans, LA.

Kostrzewa RM and LC Walker (1976) Altered development of mouse central noradrenergic neurons following

prenatal treatment with 6-hydroxydopa. 60th

Federation Am. Soc. Exp. Biol. meeting, Anaheim, CA.

Kostrzewa RM, TH Joh, AJ Kastin, C Christensen and MA Spirtes (1976) Effects of L-prolyl-L-leucyl-glycine aide

(MIF-I) on dopaminergic neurons. Bicentennial Neuro-peptide Conference, Philadelphia, PA.

Spirtes MA, NP Plotnikoff, RM Kostrzewa, CT Harston, AJ Kastin and CW Christensen (1976) Possible

association of increased rat behavioral effects and increased striatal dopamine and norepinephrine levels during the

DOPA- potentiation test. Bicentennial Neuropeptide Conference, Philadelphia, PA.

Christensen CW, CT Harston, AJ Kastin, RM Kostrzewa and MA Spirtes (1976) Preliminary investigations on

α-MSH and MIF-I. Effects on cyclic nucleotide levels in rat brain. Bicentennial Neuropeptide Conference,

Philadelphia, PA.

Kostrzewa RM (1977) Sprouting of noradrenergic terminals in rat cerebellum after 6-hydroxydopa. 8th

Am. Soc.

Neurochemistry meeting, Denver, CO.


Morgan D, JH McLean and RM Kostrzewa (1977) Comparison of 6-hydroxydopamine and 6-hydroxydopa on the

development of behavior. American Psychological Assn. meeting, San Francisco, CA.

Kostrzewa RM, AJ Kastin and S Sobrian (1978) Studies on the antiparkinsonian activity of a naturally-occurring

tripeptide, L-prolyl-L-leucyl-glycinamide. 62nd

Federation Am. Soc. Exp. Biol. meeting, Atlantic City, NJ.

Kostrzewa RM and MB Clark (1978) Stimulation of regenerative sprouting in the central nervous system by nerve

growth factor. 7th

Int=l Union of Pharmacology, Paris, France.

Kostrzewa RM and MB Clark (1978) Regenerative sprouting of noradrenergic terminals in the cerebellum. IV Int'l.

Catecholamine Symposium, Pacific Grove, CA.

Kostrzewa RM, SK Sobrian, H Fukushima and AJ Kastin (1978) Actions of L-prolyl-L-leucyl-glycine amide on

striatal enzyme activities. Huntington's Disease Symposium, San Diego, CA.

Robert TA, RL Snell and RM Kostrzewa (1978) Similarity in structure between MIF-I and dopamine: Reason for

anti-parkinsonian activity? 8th

Soc. Neuroscience Meeting, St. Louis, MO.

Clark MB, RM Kostrzewa and J King (1978) Loss of locus coeruleus perikarya following treatment of newborn rats

with 6-hydroxydopa. Anatomy Meeting, Vancouver, Canada.

Kastin AJ, RH Ehrensing, DH Coy, AV Schally and RM Kostrzewa (1979) Behavioral effects of brain peptides,

including LH-RH. 2nd

Intl. Symposium on Clinical Psycho-Neuro Endocrinology in Reproduction. Venice, Italy.

Kastin AJ, AV Schally and RM Kostrzewa (1979) Possible aminergic mediation of MSH release and of the CNS

effects of MSH and MIF-I. Am. Physiological Soc. meeting, East Lansing, MI.

Harston CT, JC Hardin and RM Kostrzewa (1979) Morphine-enhanced regeneration of central noradrenergic nerves

following 6-hydroxydopa treatment of rat pups. 9th

Soc. Neuroscience meeting, Atlanta, GA.

Kostrzewa RM and H Fukushima (1979) Growth of axonal processes from in vivo transplants of rat locus coeruleus.

9th

Soc. Neuroscience meeting, Atlanta, GA.

Kostrzewa RM, CT Harston, JC Hardin and E Kunkel-Bagden (1980) Enhanced regeneration of noradrenergic fibers

in rat cerebellum by nerve growth factor. 26th

Histochemistry Soc. meeting, New Orleans, LA.

Harston CT and RM Kostrzewa (1980) Noradrenergic sprouting in the cerebellum of "Purkinje cell degeneration"

mutant mice. 10th

Soc. Neuroscience meeting, Cincinnati, OH.

McLean JH, DN Morgan and RM Kostrzewa (1980) Behavioral effects of amphetamine in animals treated

neonatally with 6-hydroxydopa or 6-hydroxydopamine. 10th

Soc. Neuroscience meeting, Cincinnati, OH.

McLean JH, SB Hutson, BM King and RM Kostrzewa (1981) Behavioral effects of norepinephrine and/or dopamine

depletions. 11th

Soc. Neuroscience meeting, Los Angeles, CA.

Kostrzewa RM, H Fukushima and CT Harston (1982) Collateral sprouting of noradrenergic fibers in rat cerebellum

after a midbrain lesion at birth. 6th

Federation Am. Soc. Exp. Biol. meeting, New Orleans, LA.

Kunkel-Bagden E and RM Kostrzewa (1982) Influence of nerve growth factor (NGF) on growth of noradrenergic

fibers into rat cerebellum. 3rd

Southeastern Pharmacological Society meeting, Oxford, MS.

Kostrzewa RM (1982) Naloxone-reversible morphine-induced sprouting of noradren-ergic fibers in the cerebellum

of 6-hydroxydopa-treated neonatal rats. 3rd

Southeastern Pharmacological Society meeting, Oxford, MS.

Kostrzewa RM and D Klisans-Fuenmayor (1983) Naloxone-reversible morphine- enhanced sprouting of

noradrenergic fibers in rat brainstem and cerebellum. 34th

Am. Soc. Pharmacology & Exp. Ther. meeting,

Philadelphia, PA.

Kostrzewa RM and D Klisans-Fuenmayor (1983) Collateral sprouting of noradrenergic fibers in rat brainstem and

cerebellum after dorsal lesions in neonatal rats; failure of 6-hydroxydopa to modify the response. 13th

Soc.

Neuroscience meeting, Boston, MA.

Kunkel-Bagden E and RM Kostrzewa (1984) Morphine-induced alterations of development of noradrenergic fiber

projections in rat brain following a dorsal bundle lesion. 68th

Federation Am. Soc. Exp. Biol. meeting, St. Louis,

MO.

Kostrzewa RM, D Klisans-Fuenmayor and JC Hardin (1984) Naloxone-reversible morphine-induced destruction of

coeruleus cells accompanies enhanced recovery of noradrenergic fibers in brains of rats treated as neonates with

6-hydroxydopa. 9th

Int=l Union of Pharmacology, London, England.

Hsi T, D Liu, P Cohenour, R Rhagavan, L Lin, P Lin, R Kostrzewa, RE Lehr and CL Blank (1984) Improved selectivity

in the chemical destruction of noradrenergic neurons. 9th

Int=l Union of Pharmacology, London, England.

Lin P, R Rhagavan, RE Lehr, RM Kostrzewa, S Sasa and CL Blank (1984) 5-Amino- 2,4-dihydroxy-α-

methylphenethylamine provides more selective noradrenergic destruction than 6-hydroxydopamine. 14th

Soc.

Neuroscience meeting, Anaheim, CA.

Kostrzewa RM, D Klisans-Fuenmayor and JC Hardin (1984) Naloxone-reversible morphine-induced destruction of

coeruleus cells accompanies enhanced recovery of noradrenergic fibers in brains of rats treated as neonates with

6-hydroxydopa. Southeast section, Soc. Toxicology Meeting, Johnson City, TN.

Kunkel-Bagden E and RM Kostrzewa (1985) Opioids fail to alter recovery from a dorsal bundle lesion. 16th

Am.

Soc. Neurochemistry meeting, Baltimore, MD.


Kostrzewa RM, D Klisans-Fuenmayor and JC Hardin (1986) Opioid-induced destruction of locus coeruleus cells in

6-hydroxydopa-treated neonatal rats. 16th

Soc. Neuroscience meeting, Washington, DC.

White TG and RM Kostrzewa (1987) Transient reduction of 3H-spiroperidol (

3H-SP) binding to striatal tissue

following chronic administration of prolyl-leucyl- glycinamide (PLG) in MPTP-treated mice. 71st Federation Am.

Soc. Exp. Biol. meeting, Washington, DC.

Kostrzewa RM, AJ Kastin, DH Coy, R Brus, H Criswell and PS Coogan (1987) [D-ALA2,F5-PHE

4]-dynorphin

amide, an opioid analgesic with lethal properties. 17th

Soc. Neuroscience meeting, New Orleans, LA.

Kostrzewa RM and MI Saleh (1988) Attenuation of SCH 23390-induced ontogenic impairment of rat striatal

dopamine D-1 receptors by L-prolyl-l-leucyl- glycinamide (PLG). 18th

Soc. Neuroscience meeting, Toronto.

Saleh MI and RM Kostrzewa (1988) Attenuation of spiroperidol-induced impairment of rat striatal dopamine D-2

receptors by L-prolyl-l-leucyl-glycinamide (PLG). 18th

Soc. Neuroscience meeting, Toronto.

Gong L, DS Chi, EA Daigneault and RM Kostrzewa (1989) Inhibitory effects of MPTP and vitamin E on

interleukin-2 (IL-2) production in mice. 10th

Southeastern Pharmacological Society meeting, Augusta, GA.

Hamdi A and RM Kostrzewa (1989) Enhanced yawning response to the dopamine D-2 agonist, LY171555, in adult

rats that were treated in development with LY171555. 10th

Southeastern Pharmacological Society meeting,

Augusta.

Hamdi A and RM Kostrzewa (1989) Enhanced yawning response to the dopamine D-2 agonist, LY171555, in adult

rats that were treated in development with LY171555. 19th

Soc. Neuroscience meeting, Phoenix, AZ.

Kostrzewa RM and A Hamdi (1989) Enhanced stereotypic responses to dopamine agonists in adult rats that were

treated in development with SKF38393. 19th

Soc. Neuroscience meeting, Phoenix, AZ.

Kostrzewa RM (1989) Dopamine agonists modify the development of brain D1 and D2 receptor responsiveness.

Plenary Session, 14th Southeast Section, Soc. Exp. Biol. Med. meeting, Johnson City, TN.

Hamdi A and RM Kostrzewa (1990) Enhanced stereotypic responses to dopamine agonists in adult rats that were

treated in development with both SKF38393 and 6-OHDA. 14th

Southeast Section, Soc. Exp. Biol. Med. meeting,

Johnson City, TN, 1989; Proc. Soc. Exp. Biol. Med. 194, 375.

Gong L, DS Chi, EA Daigneault and RM Kostrzewa (1990) Effects of MPTP and vitamin E on interleukin-2 (IL-2)

production in mice. 14th

Southeast Section, Soc. Exp. Biol. Med. meeting, Johnson City, TN, 1989; Proc. Soc. Exp.

Biol. Med. 194, 378.

Arbogast LY, JK Neumann, RM Kostrzewa and BW Arbogast (1990) Response of toxicity preventing activity levels

to psychological stress. 14th

Southeast Section, Soc. Exp. Biol. Med. meeting, Johnson City, TN, 1989; Proc. Soc.

Exp. Biol. Med. 194, 378.

Neumann JK, DS Chi, BW Arbogast, RM Kostrzewa and LM Harvill (1990) Relation-ship of blood groups to

self-reported behavior patterns in MI patients. 14th

Southeast Section, Soc. Exp. Biol. Med. meeting, Johnson City,

TN, 1989; Proc. Soc. Exp. Biol. Med. 194, 379.

Arbogast LY, JK Neumann, RM Kostrzewa and BW Arbogast (1990) Decreased VLDL toxicity preventing activity

in response to a reverse mirror drawing stressor. Southern Association of Agricultural Scientists, Little Rock, AK.

Chi DS, L Gong, EA Daigneault and RM Kostrzewa (1990) Effects of MPTP and vitamin E (VE) on immune

functions. Joint meeting, Am. Soc. Biochem. Molec. Biol. and Am. Assn. Immunology meeting, New Orleans, LA.

Kostrzewa RM, A Hamdi and FP Kostrzewa (1990) Production of prolonged super-sensitization of dopamine D2

receptors. 11th Int=l Union of Pharmacology, Amsterdam, The Netherlands.

Gong L, EA Daigneault, DS Chi, RW Acuff and RM Kostrzewa (1991) The effective-ness of neurotoxin MPTP in

mice treated with alpha-tocopherol. Joint 11th

Southeastern Pharmacological Society and 2nd

Am. College of

Clinical Pharmacology meeting, Johnson City, TN, 1990; J. Clin. Pharmacol. 31, 276.

Kostrzewa RM, A Hamdi and L Gong (1991) Enhanced spiperone- and SKF 38393- induced oral activity in rats

after neonatal intracerebroventricular treatment with 6-hydroxydopamine. Joint 11th

Southeastern Pharmacological

Society and 2nd

Am. College of Clinical Pharmacology meeting, Johnson City, TN 1990; J. Clin. Pharmacol. 31,

264.

Kostrzewa RM, R Brus and J Guo (1991) Production of supersensitized D2 and/or D3 receptors in rats. 21st Soc.

Neuroscience meeting, New Orleans, LA.

Gong L, EA Daigneault and RM Kostrzewa (1991) Mediation of enhanced SKF 38393-induced oral activity by a

serotonin system. 21st Soc. Neuroscience meeting, New Orleans, LA.

Arbogast BW, JK Neumann, RM Kostrzewa, LY Arbogast and SC Leeper (1992) Effect of acute psychological

stress on serum VLDL protective activity. 25th

Lofland Conference, Boston, MA.

Brus R, R Kostrzewa, R Szkilnik and A Plech (1992) Effect of quinpirole, a dopamine D2 receptor agonist, on

learning and memory of conditioned avoidance reflex (CAR) in rats. 11th

Congress of the Polish Pharmacological

Society, Gdansk, Poland. Pol. J. Pharmacol. 44 (Suppl.), 105-106.

Jdrusiak J, RM Kostrzewa and R Brus (1992) Influence of dopamine receptor agonists and antagonists on the

cardiovascular actions of TRH in rats. 11th

Congress of the Polish Pharmacological Society, Gdansk, Poland. Pol.

J. Pharmacol. 44 (Suppl.), 148-149.


Kostrzewa RM, L Gong and R Brus (1992) Serotonin (5-HT) systems mediate dopamine (DA) receptor

supersensitivity. 1st Intl Congress of the Polish Neuroscience Society, Warsaw, Poland. Acta Neurobiol. Exp. 52,

126.

Gong L, RM Kostrzewa, RW Fuller and KW Perry (1992) Ontogenic supersensitization of dopamine D1 receptors.

13th

Southeastern Pharmacological Society meeting, Charleston, SC.

Leeper SC, JK Neumann, LY Arbogast, RM Kostrzewa and BW Arbogast (1992) Effect of stress on the ability of

human serum to protect against VLDL injury of aortic endothelial cells in culture. 65th

American Heart Assn.

meeting, New Orleans, LA.

Arbogast BW, JK Neumann, LY Arbogast, SC Leeper and RM Kostrzewa (1993) Transient loss of serum protective

activity following short term stress: a possible biochemical link between stress and atherosclerosis. Experimental

Biology meeting, New Orleans, LA.

Brus R, RM Kostrzewa, M Rykaczewska and A Plech (1993) Nadwrazliwosc osrodkowych receptorow

dopaminergicznych: badania behawioralne. [Supersensitivity of central dopamine receptors: a behavioral study].

2nd

Neuropsychopharmacological Days, Ustro, Jaszowiec, Poland.

Feliska W, R Brus, M Rykaczewska, A Plech, RM Kostrzewa and R Szkilnik (1993) Wplyw ethanolu stosowanego

w okresie prenatalnym na readtywnosc osrodkowych receptorow dopaminergicznych u szczurow. [Effect of

prenatal ethanol on reactivity of central dopaminergic receptors in rats]. 2nd

Neuropsychopharmacological Days,

Ustro, Jaszowiec, Poland.

Brus R, W Feliska, RM Kostrzewa, M Rykaczewska, A Plech, R Szkilnik and H Jakrzewska (1993) Cadmium

modulates reactivity of central dopamine receptors to agonists in rats prenatally exposed to ethanol. Conference of

the Polish Pharmacological Society and Polish Toxicological Society, Bialowieza, Poland.

Brus R, R Szkilnik, RM Kostrzewa, M Rykaczewska, A Plech, P Nowak and H Jakrzewska (1993) Effect of electric

foot shock on reactivity of central dopaminergic receptors to agonists in rats. 19th

Congress of the Polish

Physiological Society, Toru, Poland.

Kostrzewa RM, R Brus, KW Perry and RW Fuller (1993) 5,7-Dihydroxytryptamine destruction of serotonin fibers

eliminates the enhanced oral activity response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats. 23rd


Gong L, RM Kostrzewa, R Brus, EA Daigneault, RW Fuller and KW Perry (1993) Ontogenetic supersensitization of

dopamine D1 receptors occurs without a change in D1 high affinity sites. 23rd

Soc. Neuroscience Meeting,

Washington, DC.

Huang N-Y, RM Kostrzewa and MD Miyamoto (1993) Chronic haloperidol treatment greatly increases spontaneous

oral activity in neonatal 6-hydroxydopamine-lesioned rats. 23rd


Brus R, RM Kostrzewa, KW Perry and RW Fuller (1994) Serotonin fibers and central dopamine D1 receptor

supersensitivity. 3rd

Neuropsychopharmacological Days, Ustro, Jaszowiec, Poland.

Plech A, R Brus and RM Kostrzewa (1994) Enhanced oral activity responses to intrastriatal SKF-38393 and m-CPP

are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. 3rd


Ustro, Jaszowiec, Poland.

Kostrzewa RM, L Gong, N-Y Huang and R Brus (1994) Serotonin-dopamine interactions in the genesis of oral

activity. 5th

Eur. Behav. Pharmacological Soc. meeting, Berlin, Germany. Behav. Pharmacol. 5, Suppl. 1, 11.

Brus R, RM Kostrzewa, R Szkilnik, M Rykaczewska, A Plech, P Nowak and H Jakrzewska (1994) Electric foot

shock stress and reactivity of central dopamine (D1, D2) receptors to agonists in male and female rats. 5th

Eur.

Behav. Pharmacological Soc. Meeting, Berlin, Germany. Behav. Pharmacol. 5, Suppl. 1, 110-111.

Brus R, RM Kostrzewa, R Szkilnik, W Feliska, A Plech, M Rykaczewska and H Jakrzewska (1994) Reactivity of

the central dopamine (D1, D2) receptors to agonists in rats prenatally exposed to ethanol and cadmium. 5th

Eur.

Behav. Pharmacological Soc. Meeting, Berlin, Germany. Behav. Pharmacol. 5, Suppl. 1, 126.

Brus R, R Szkilnik, W Feliska, RM Kostrzewa, A Plech and H Jakrzewska (1994) Prenatal exposure to ethanol and

reactivity of central dopaminergic, serotoninergic and muscarinic receptors in rat offspring. 4th

Joint Meeting of

Hungarian, Italian and Polish Pharmacological Societies, Poznan, Poland. Pol. J. Pharmacol. 46, 218-219.

Brus R, RM Kostrzewa, R Szkilnik, I Jdrusiak, J Konecki and M Gowacka (1994) Dopaminergic neuronal system

and glucose metabolism in the rat brain. 4th Joint Meeting of Hungarian, Italian and Polish Pharmacological

Societies, Poznan, Poland. Pol. J. Pharmacol. 46, 283.

Kostrzewa RM, R Brus, RW Fuller and KW Perry (1995) 5,7-Dihydroxytryptamine (5,7-DHT) lesions of serotonin

(5-HT) fibers alter dopamine (DA) agonist-induced behaviors in rats. 34th

Soc. Toxicology Meeting, Baltimore,

MD. The Toxicologist 15, 246.

Huang N-Y and RM Kostrzewa (1995) Enhanced oral activity persists in neonatal 6-hydroxydopamine (6-OHDA)-

lesioned rats withdrawn from long-term haloperidol treatment. 34th

Soc. Toxicology Meeting, Baltimore, MD. The

Toxicologist 15, 246.


Kostrzewa RM, R Brus, KW Perry and RW Fuller (1995) Sensitization to dopamine (DA) and 5-hydroxytryptamine

(5-HT) agonists is not correlated with alterations in DA and 5-HT contents of neostriatum after neonatal

intrastriatal 6-hydroxydopamine injections in rats. 2nd

Int=l Congress of the Polish Neuroscience Society, Cracow,

Poland. Acta Neurobiol. Exp. 55 (Suppl.), 13.

Brus R, R Szkilnik, P Nowak and RM Kostrzewa (1995) Nitric oxide (NO) and central dopamine (DA) receptor

supersensitivity in rats. 2nd

Int=l Congress of the Polish Neuroscience Society, Cracow, Poland. Acta Neurobiol.

Exp. 55 (Suppl.), 13.

Brus R, RM Kostrzewa, I Jdrusiak, R Szkilnik and L Wojtowicz (1995) In vivo voltammetric determination of

enhanced spiperone-induced release of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) in neostriatum

of rats with supersensit-ized DA D2-receptors.' 2nd

Int=l Congress of the Polish Neuroscience Society, Cracow,

Poland. Acta Neurobiol. Exp. 55 (Suppl.), 59.

Kostrzewa RM and R Brus (1995) Complementarity of dopamine and serotonin neurons in regulating motor activity.

12th

Congress of the Polish Pharmacological Society, Bydgoszcz, Poland. Pol. J. Pharmacol. 47 (Suppl.), 17-18.

Brus R, R Szkilnik, P Nowak and RM Kostrzewa (1995) Effect of NAME and arginine on central dopamine receptor

reactivity in rats. 12th

Congress of the Polish Pharmacological Society, Bydgoszcz, Poland. Pol. J. Pharmacol. 47

(Suppl.), 54.

Brus R, P Nowak, R Szkilnik and RM Kostrzewa (1995) Effect of mCPP, a 5HT2C central receptor agonist, on

grooming behavior in male and female rats after neonatally induced chemical serotoninectomy. 12th

Congress of the

Polish Pharmacological Society, Bydgoszcz, Poland. Pol. J. Pharmacol. 47 (Suppl.), 54.

Brus R, R Szkilnik, P Nowak and RM Kostrzewa (1996) Effect of m-CPP, a 5-HT2 central receptor agonist, on

grooming behavior in male and female rats after neonatally induced chemical serotoninectomy. 20th

Congress of the

Polish Physiological Society, Wrocaw, Poland.

Brus R, R Szkilnik, P Nowak and RM Kostrzewa (1996) Effect of NAME and arginine on central dopamine receptor

reactivity in rats. 20th

Congress of the Polish Physiological Society, Wrocaw, Poland.

Brus R, R Szkilnik, RM Kostrzewa, U Mikoajun and W Tramer (1996) 6-Hydroxydop-amine, 5,7-

dihydroxytryptamine and reactivity of the central dopamine D3 receptor to quinpirole. 20th

Congress of the Polish

Physiological Society, Wrocaw, Poland.

Kostrzewa RM, R Brus, KW Perry and RW Fuller (1996) Enhanced quinpirole-induced oral activity in rats lesioned

with 6-hydroxydopamine during ontogeny and with 5,7-dihydroxytryptamine during adulthood. 26th

Soc.

Neuroscience Meeting, Washington, DC.

Kostrzewa RM and N-Y Huang (1997) Serotonin antagonists attenuate oral dyskinesia in 6-hydroxydopamine-

lesioned rats during withdrawal from chronic haloperidol. Am. Soc. Pharmacology & Exp. Ther. Meeting, San

Diego, CA, 1997. The Pharmacologist 39, 120.

Kostrzewa RM (1997) Observations relative to the neurotoxicity and neurotoxic potential of amino acids. In the

symposium Neurotoxicity and Neurotoxic Potential of Amino Acids. 5th

Int=l Congress on Amino Acids,

Chalkidiki, Greece.

Kostrzewa RM and R Brus (1997) Destruction of catecholamine-containing neurons by 6-hydroxydopa, an

endogenous amine oxidase cofactor. In the symposium Neuro-toxicity and Neurotoxic Potential of Amino Acids. 5th

Int=l Congress on Amino Acids, Chalkidiki, Greece. Amino Acids 13, 60.

Brus R, R Szkilnik, A Kasperska, J Owicimska and R.M. Kostrzewa.(1997) Effect of the amino acid L-arginine

and its analog nitro-L-arginine methyl ester HCl (L-NAME) on central dopamine (DA) receptor reactivity. 5th

Int=l

Congress on Amino Acids, Chalkidiki, Greece, 1997. Amino Acids 13, 29.

Brus R, R Szkilnik, A Kasperska, J Owicimska and RM Kostrzewa (1997) Effect of the aminoacid L-arginine and

its analog nitro-L-arginine methyl ester HCl (L-NAME) on central dopamine (DA) receptor reactivity. 3rd

Intl

Congress of the Polish Neuroscience Society, d, Poland. Acta Neurobiol. Exp. 57, 22.

Kostrzewa RM and R Brus (1997) Dopamine receptor supersensitivity. In Satellite Symposium Dopamine: New

Trends in Receptor Research and Therapeutic Implications 3rd

Int=l Congress of the Polish Neuroscience Society,

d, Poland. Acta Neurobiol. Exp. 57, 3.

Kostrzewa RM, R Brus and KW Perry (1997) Ontogenetic intrastriatal 6-OHDA lesions enhance m-

chlorophenylpiperazine- (m-CPP-) induced vacuous chewing in rats. 27th

Soc. Neuroscience Meeting, New

Orleans, LA.

Brus R, J Owicimska, L Glenn and RM Kostrzewa (1997) Quinpirole, but not 7-OH-DPAT, induces oral activity

and locomotor activity in rats. 27th

Soc. Neuroscience Meeting, New Orleans, LA.

Brus R, J Owicimska and RM Kostrzewa (1998) Comparison of some behavioral and biochemical effects of two

central dopamine agonists (Quinpirole and 7-OHDPAT) in rats. XIII Int=l Union of Pharmacology Congress,

Munich, Germany. Naunyn-Schmiedeberg=s Arch. Pharmacol. 358, suppl. 1, R96.


Brus R, A Kasperska, P Nowak, R Szkilnik and RM Kostrzewa (1998) Effects of nitric oxide donor (L-Arginine)

and nitric oxide synthase inhibitor (L-NAME) on reactivity of central dopamine receptors in rats. XIII Int=l Union

of Pharmacology Congress, Munich, Germany. Naunyn-Schmiedeberg=s Arch. Pharmacol. 358, suppl. 1, R95.

Kostrzewa, R.M. and R. Brus. Coordinate dopamine and serotonin neurochemical actions: relevance to drug actions.

XIII Polish Pharmacological Society Congress, Katowice, Poland, September 1998.

Kasperska A, R Brus, R Szkilnik and RM Kostrzewa (1998) Effect of the nitric oxide (NO) synthase inhibitor (L-

NAME) and NO donors (L-ARGININE, MOLSIDOMINE) on amphetamine-induced stereotypy behavior in rats.

XIII Polish Pharmacological Society Congress, Katowice, Poland.

Owicimska J, R Brus and RM Kostrzewa (1998) Comparison of some behavioral effects of two central dopamine

(DA) agonists: Quinpirole and 7-OH-DPAT in male and female rats. XIII Polish Pharmacological Society

Congress, Katowice, Poland.

Tizabi Y, VA Louis, RL Copeland Jr, R Brus and RM Kostrzewa (1998) Nicotinic cholinergic systems mediate

quinpirole-induced behavior in rats. 28th

Soc. Neuroscience Meeting, Los Angeles, CA.

Tizabi Y and RM Kostrzewa (1998) Involvement of nicotinic cholinergic system in quinpirole-induced behaviors.

Soc. Biol. Psychiatry, Washington, DC.

Kostrzewa RM, JP Kostrzewa and R Brus (1999) Susceptibility of neostriatal dopamine nerve terminals to oxidative

injury by L-DOPA. In the symposium Neurobiology of the ventral basal ganglia loop. 6th

Int=l Congress on Amino

Acids: Satellite meeting on Neurobiology, Bonn, Germany. Amino Acids 17:12.

Brus R, A Kasperska, A Sokoa and RM Kostrzewa (1999) Effect of the aminoacid L-arginine and its analog nitro

L-arginine methyl ester (L-NAME) on amphetamine and apomorphine induced stereotyped behavior and DOPAC

release in the striatum of rats. 6th

Int=l Congress on Amino Acids: Satellite meeting on Neurobiology, Bonn,

Germany. Amino Acids 17:19.

Brus R, J Owicimska, R Szkilnik, A Sokola dnd RM Kostrzewa (1999) Discrimination between dopamine (DA)

D2 and D3 receptor-mediated events: DOPAC release in the striatum and some behavioral effects of quinpirole and

7-OH-DPAT in rats. 30th

Am. Soc. Neurochemistry meeting, New Orleans, LA, USA, March 1999. J. Neurochem.

72 Suppl., p. S77.

Kostrzewa RM, R Brus and J Owicimska (1999) Insights on neurochemical mechanisms of hyperactivity and

potentially new therapeutic strategies. In the symposium, New Therapeutic Strategies for Neurologic and

Psychiatric Disorders. 4th

Polish Int=l Neuroscience Meeting, Gdansk, Poland. Acta Neurobiol. Exp. 59:217.

Kasperska A, R Brus, A Sokoa and RM Kostrzewa (1999) Effect of L-arginine and nitro-L-arginine methyl ester

(L-NAME) on amphetamine and apomorphine induced stereotyped behavior and DOPAC release in the striatum of

rats. 4th


Brus R, J Owicimska, R Szkilnik, A Sokoa and RM Kostrzewa (1999) Comparison of DOPAC release in the

striatum and some behavioral effects of quinpirole and 7-OH-DPAT, dopamine D2/D3 receptor agonists in rats. 4th


Brus R, P Nowak, R Szkilnik, RM Kostrzewa and W Kiszka (1999) Catecholamine levels in rat brain prenatally

exposed to mercury. Polish Toxicological Society Meeting, Augustow, Poland.

Kostrzewa RM, JP Kostrzewa and R Brus (1999) Neurotoxicity and neurodegeneration: Among the shifting sand

dunes of protection. Fundación Cerebro y Mente Intl meeting on Neurotoxicology, Degeneration and Protection in

Brain Disease States, Mojácar (Almeria) Spain.

Kostrzewa RM, JP Kostrzewa and R Brus (1999) Suppression of hydroxyl radical by dopaminergic innervation.

Fundación Cerebro y Mente Intl meeting on Neurotoxicology, Degeneration and Protection in Brain Disease

States, Mojácar (Almeria) Spain.

Kostrzewa JP, RM Kostrzewa and R Brus (2000) Dopamine innervation and L-DOPA treatment suppress hydroxyl

radical formation in rat striatum. 6th

Internet World Congress on Biomedical Sciences, Madrid, Spain.

Kostrzewa JP, RM Kostrzewa and R Brus (2000) Suppression of hydroxyl radical by dopaminergic innervation. East

Tennessee State University, 16th

annual Student Research Forum, Johnson City, TN.

Owicimska J, P Nowak, U Mikoajun, R Szkilnik, R Brus and RM Kostrzewa (2000) Effects of the central

serotonin receptor agonists on locomotor activity in animal model of attention deficit hyperactivity disorder

(ADHD). 9th

Neuropsychopharmacological Days, Ustro-Jaszowiec, Poland. Pol. J. Pharmacol. 52: 152.

Owicimska J, P Nowak, R Szkilnik, R Brus and RM Kostrzewa (2000) Comparison of behavioral effects induced

by two central dopamine D3 receptor agonists: 7-OH-DPAT and quinpirole in neonatally 6-OHDA-lesioned male

and female rats. 9th

Neuro-psychopharmacological Days, Ustro-Jaszowiec, Poland. Pol. J. Pharmacol. 52:152-

153.

Kostrzewa JP, RM Kostrzewa and R Brus (2000) Suppression of hydroxyl radical by dopaminergic innervation.

Joint Am. Soc. Biochem. Molec. Biol. and Am. Soc. Pharmacology & Exp. Ther. meeting, Boston.


Kostrzewa RM, JP Kostrzewa and R Brus (2001) Neurotoxic and neuroprotective properties of dopamine: relevance

to Parkinson=s Disease. Int=l Congress on Neurotoxicity as a Mechanism for Neurodegenerative Disorders: Basic

and Clinical Aspects. Pucón, Chile.

Brus R and RM Kostrzewa (2001) Receptor sensitization as a manifestation of neurotoxicity. Int=l Congress on

Neurotoxicity as a Mechanism for Neurodegenerative Disorders: Basic and Clinical Aspects. Pucón, Chile.

Kostrzewa RM, R Brus and JP Kostrzewa (2001) Insidious dopamine: Provocateur or protective agent in

Parkinson=s disease. 10th

Neuropsychopharmacological Days, Ustro, Jaszowiec, Poland. Pol. J. Pharmacol.

53(2): 165-166.

Kostrzewa RM, JP Kostrzewa and R Brus (2001). Suppression of spontaneous hydroxyl radical formation in

dopamine-denervated neostriatum, but enhancement by glutamate. 7th

Int=l Congress on Amino Acids and Proteins,

Vienna, Austria. Amino Acids 21(1): 39.

Kostrzewa RM, JP Kostrzewa and R Brus. Involvement of dopaminergic neurons in generating and sequestering

reactive oxygen species. In the symposium Complementary Neuroprotective Roles of Dopaminergic and

Serotonergic Neurons, XIV Int=l Congress of the Polish Pharmacological Society, Kraków, Poland, September

2001. Pol. J. Pharmacol. 53 (suppl.): 49-50, 2001.

Brus R, P Nowak, A Sokoa, RM Kostrzewa and J Shani (2001) Behavioral and biochemical effects of new central

dopamine D3 (U-99194A) and D4 (U-101958) receptor antagonists in rats. 5th

Int=l Congress of the Polish

Neuroscience Society, Toru, Poland. Acta Neurobiol. Exp. 61: 197.

Nowak P, R Brus, R Szkilnik and RM Kostrzewa (2001) Effects of the central dopamine and serotonin receptor

agonists on biogenic amines release in rats= brain with experimental model of attention deficit hyperactivity

disorder (ADHD). In vivo brain microdialysis study. 5th

Int=l Congress of the Polish Neuroscience Society, Toru,

Poland. Acta Neurobiol. Exp. 61: 199.

Brus R, P Nowak, R Szkilnik and RM Kostrzewa (2001) Effect of amphetamine and quinpirole on dopamine and its

metabolites release in the brain of neonatal quinpirole-primed rats. An in vivo microdialysis study. XIV Congress

of the Polish Pharmacological Society, Cracow, Poland. Pol. J. Pharmacol. 53 (suppl.): 107, 2001.

Szkilnik R, R Brus, P Nowak, A Sokoa, Labus, RM Kostrzewa and J Shani (2001) Effect of prenatal manganese

exposure on behavior, biogenic amine levels and their release in the brain of adult rats. XIV Congress of the Polish

Pharmacological Society, Cracow, Poland.

Kostrzewa RM, JP Kostrzewa and R Brus (2001) Destructive propensities of perinatal neurotoxins on brain

development and function. Fundación Cerebro y Mente International Meeting on Neurodevelopmental Liabilities in

Brain Disease States. Mojácar, Spain.

Brown RW, JT Gass, IA Click, SK Thacker, RL Norris and RM Kostrzewa. Ontogenetic quinpirole treatment

produces spatial memory deficits and reaching accuracy enhancement in adult rats. 31st Society for Neuroscience

Meeting, San Diego, CA, 2001.

Nowak P, R Brus and RM Kostrzewa. Determination of hydroxyl radical from in vivo microdialysates of the rat

neostriatum: methodological aspects and preliminary findings. 11th

Neuropsychopharmacological Days, Ustro-

Jaszowiec, Poland. Pol. J. Pharmacol. 54(2): 198, 2002.

Kostrzewa RM and R Brus. Serotonin and Parkinson=s disease. 11th

Neuropsycho-pharmacological Days, Ustro-

Jaszowiec, Poland. Pol. J. Pharmacol. 54(2): 178-179, 2002.

Brown RW, KD Thompson, KL Thompson, JJ Ward, SK Thacker and RM Kostrzewa. Nicotine alleviates cognitive

and motor deficits produced by ontogenetic quinpirole treatments. 32nd

Soc. Neurosci. Meeting, Orlando, FL, 2002.

Soc. Neurosci. Abstr. 305.2.

Thompson KD, DS White, JJ Ward, R Kostrzewa and RW Brown (2002) Ontogenetic quinpirole treatments produce

behavioral deficits that are alleviated by nicotine. Southeastern Psychol. Assn., Orlando, FL.

Brus R, P Nowak and RM Kostrzewa. Co-morbid ontogenetic effects of cadmium and ethanol in rats evidenced by

altered in vivo microdialysate levels of striatal dopamine, DOPAC and HVA after amphetamine or haloperidol.

32nd

Soc. Neurosci. Meeting, Orlando, FL, 2002. Soc. Neurosci. Abstr. 606.18.

Kostrzewa RM, JP Kostrzewa and R Brus. Dopamine receptor supersensitivity as an index of neurotoxicity. 1st

Neurotoxicity Soc. Meeting, La Serena, Chile, April 2003.

Kostrzewa RM, JP Kostrzewa, P Nowak and R Brus. Priming as a process for producing dopamine D2 receptor

supersensitization: relevance in psychiatric disorders. 12th Neuropsychopharmacological Days, Ustro-Jaszowiec,

Poland, May 2003. Pol. J. Pharmacol. 55, 281-284, 2003.

Kostrzewa RM, JP Kostrzewa, R Brus and P Nowak. L-Dihydroxyphenylalanine treatment reduces hydroxyl radical

levels in tissue and microdialysates of dopamine-denervated rat striatum. 8th

Int=l Congress on Amino Acids and

Proteins, Rome, Italy. September 2003. Amino Acids 25(2), 157, 2003.

Kostrzewa RM, JP Kostrzewa, RA Kostrzewa, P Nowak and R Brus. Dopamine agonist priming in intact and

dopamine-lesioned rats: implications for motor dyskinesias. Fundación Cerebro y Mente International Meeting on

Genes and Environment Interplay in Neuropsychiatric Disorders, Mojácar, Spain, October 2003.


Kostrzewa RM, P Nowak, R Brus, RA Kostrzewa and JP Kostrzewa. Peculiarities of Parkinson's disease and L-DOPA

therapy. Studies in an animal model of Parkinson’s disease. XV International Congress of the Polish Pharmacological

Society, Poznan, Poland, September 2004.

Nowak P, A Bortel, J Dąbrowska, Ł Labus, R Brus and RM Kostrzewa. Effect of neonatal DSP-4 administration on

biogenic amine levels and amphetamine-induced release into microdialysates of adult rat frontal cortex. XV

International Congress of the Polish Pharmacological Society, Poznan, Poland, September 2004.

Brus R, P Nowak, Ł Labus, A Bortel, J Dąbrowska and RM Kostrzewa. Neonatal lesion of noradrenergic neurons in rat

brain: interaction with the dopaminergic system. XV International Congress of the Polish Pharmacological Society,

Poznan, Poland, September 2004.

McCoy MT, KG Becker, WH Wood 3rd, DR Teichberg, RW Brown, RM Kostrzewa and JL Cadet. Differential

quinpirole-induced transcriptional responses in the rat striatum and nucleus accumbens: evidence from microarray

analysis. Society for Neuroscience, San Diego, CA, October 2004.

Thacker SK, MK Perna, KS Smith, RM Kostrzewa and RW Brown. Chronic olanzapine treatment eliminates D2

supersensitization and cognitive deficits produced by neonatal quinpirole treatment. Intl. Soc. Behav. Neurosci., Key

West, FL, June 2004.

Thacker SK, MK Perna, KS Smith, RM Kostrzewa and RW Brown. Chronic olanzapine treatment eliminates D2

supersensitization and cognitive deficits produced by neonatal quinpirole treatment. Society for Neuroscience, San

Diego, CA, October 2004.

Kostrzewa RM, JP Kostrzewa, P Nowak, RA Kostrzewa and R Brus. Serotonin systems mediate and modulate

dopamine in a Parkinsonian rodent model. Viña del Mar, Chile, April 2005. Neurotox. Res. 8(3,4), 319.

Kostrzewa JP and RM Kostrzewa. p-Chloroamphetamine enhances dopamine release (striatal in vivo

microdialysates) after 5-HT lesion of Parkinsonian rats. Viña del Mar, Chile, April 2005. Neurotox. Res. 8(3,4),

321.

Nowak P, Ł Labus, A Bortel, J Dąbrowska, R Szkilnik, RM Kostrzewa and R Brus. Simultaneous neonatal lesion of

noradrenergic and serotoninergic neurons in rat brain: interaction with the dopaminergic system. 14th

Neuropsychopharmacological Days, Ustro-Jaszowiec, Poland, May 2005. Pol. J. Pharmacol. 57, x-y, 2005.

Brus R, P Nowak, Ł Labus, A Bortel, J Dąbrowska and RM Kostrzewa. Neonatal lesion of noradrenergic neurons in

rat brain: interaction with the dopaminergic system. II Neurotoxicity Society meeting, Viña del Mar, Chile, April

2005.

Nowak P, A Bortel, J Dąbrowska, Ł Labus, R Brus and RM Kostrzewa. Effect of neonatal DSP-4 administration on

biogenic amine levels and amphetamine-induced release into microdialysates of adult rat frontal cortex. II Neurotoxicity

Society meeting, Viña del Mar, Chile, April 2005.

Nowak P, Ł Labus, A Bortel, J Dąbrowska, R Szkilnik, RM Kostrzewa and R Brus (2005) Simultaneous neonatal

lesion of noradrenergic and serotonergic neurons in rat brain: interaction with the dopaminergic system. 14th

Neuropsychopharmacological Days, Ustro-Jaszowiec, Poland, May 2005. Pharmacological Reports 57, 260-261,

2005.

Kostrzewa RM and R Brus. Modeling tardive dyskinesia: predictive new treatment. 14th

Neuropsychopharmacological Days, Ustro-Jaszowiec, Poland, May 2005. Pharmacological Reports 57, 262-264,

2005.

Nowak P, L Labus, RM Kostrzewa and R Brus (2005) Central noradrenergic system lesion by DSP-4 prevents quinpirole

ontogenic sensitization to quinpirole-induced yawning in rats. Pharmacological Reports 57, 316, 2005.

Kostrzewa RM, JP Kostrzewa, R Brus, RA Kostrzewa and P Nowak (2005) Proposed animal model of severe

Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum. 16th

Int’l

Congress on Parkinson’s Disease and Related Disorders, Berlin, Germany, June 5-9, 2005.

Kostrzewa RM and R Brus (2005) Persistent vacuous chewing and treatment strategy in a model of tardive

dyskinesia. Fundación Cerebro y Mente International Meeting on Implications of Comorbidity for Etiology and

Treatment of Neuropsychiatric Disorders, Mojácar, Spain, October 2005.

Brown RW, SK Thacker, MK Perna, KJ Smith, JJ Ward, TL Schaefer, MT Williams and RM Kostrzewa (2005) Chronic

adulthood olanzapine treatment eliminates D2 receptor priming and cognitive deficits produced by neonatal quinpirole

treatment. Society for Neuroscience, Washington DC, November 2005.

Kostrzewa RM and R Brus (2006) Selective neurotoxins and neuroscience – approaching the golden anniversary,

15th

Neuropsychopharmacological Days, Ustro, Jaszowiec, Poland, May 2006.

Kostrzewa RM, JA Correll, KN Thompson, ID Longacre, D Yin, ML Woodruff and RW Brown (2006) Nicotine

sensitization in adolescent beta arrestin-2 knockout mice. Society for Neuroscience, Atlanta, GA, October 2006.

Nowak P, R Szkilnik, A Bortel, J Niwinski, G Szczerbak, M Drosik, L Noras, A Kwiecinski, RM Kostrzewa and R

Brus (2007) Revelation of ‘dysplacement’ functions of monoaminergic nerves after lesions. III Neurotoxicity

Society Meeting, Pucon Chile, March 2007.


Nowak P, A Bortel, J Jochem, K Zwirska-Korczala, J Niwinski, M Drosik, L Noras, RM Kostrzewa and R Brus

(2007) Ontogenetic noradrenergic lesion alters histaminergic activity in adult rats. III Neurotoxicity Society

Meeting, Pucon Chile, March 2007.

Nowak P, A Bortel, Ł Noras, G Szczerbak, J Gorzałek, A Kwieciński, R Szkilnik, M Drosik, RM Kostrzewa and R

Brus (2007) Effect of dual ontogenetic lesions of noradrenergic and dopaminergic neurons on biogenic amine

levels in rat brain, and reactivity of serotonin and dopamine receptors. Neurotoxicity Society Meeting, Pucon,

Chile, March 2007.

Kostrzewa RM, JP Kostrzewa, P Nowak and R Brus (2007) Serotonin in a Parkinsonian rat. III Neurotoxicity

Society Meeting, Pucon Chile, March 2007.

Kostrzewa RM and J Segura-Aguilar (2007) Neurotoxins: Where we’ve been, where we are, where we’re going.

Satellite of the III Neurotoxicity Society Meeting, Patagonia, Chile, March 2007.

Kostrzewa RM (2007) Pharmacological models of ADHD. 39th

Int’l Danube Symposium for Neurological Sciences

and Continuing Education & 1st Int’l Congress on ADHD: from Childhood to Adult Disease, Wűrzburg, Germany,

2-5 June 2007. J. Neural Transm. 114(4):XLVII, 2007.

Nowak P, J Jochem, K Zwirska-Korczala, Ł Noras, M Drosik, A Kwiecinski, RM Kostrzewa and R Brus (2007)

Effect of noradrenergic neurons lesion as neonates on histamine level in the brain and reactivity of the central

histamine receptors in adult rats. Polish Pharmacological Congress, Wrocław, Poland, Sept. 2007. Pharmacol.

Reports 59 suppl. 1, 47.

Nowak P, M Swoboda, R Szkilnik, G Szczerbak, J Josko, J Gorzałek, A Kwiecinski, RM Kostrzewa and R Brus

(2007) Nitric oxide modulates the amphetamine effect on [3H]glucose uptake in the brain of rats prenatally exposed

to lead. Polish Pharmacological Congress, Wrocław, Poland, Sept. 2007. Pharmacol. Reports 59 suppl. 1, 53-54.

Nowak P, G Szczerbak, RM Kostrzewa and R Brus (2007) Effect of prenatal lead exposure on nigrostriatal

neurotransmission and hydroxyl radicals formation in rat neostriatum. Dopaminergic-nitrenergic interaction.

Society for Neuroscience, San Diego, CA, 3-7 Nov. 2007.

Kostrzewa RM, JP Kostrzewa, R Brown and R Brus (2007) Dopamine receptor sensitivity and stereotypic / motor

behaviours. Fundación Cerebro y Mente International Meeting, Beyond Neuropsychiatric Diagnostics: Symptoms

Not Disorders. Lecture: Mazagon (Huelva), Spain, 17-21 October 2007.

Kostrzewa RM (2008) Advances in Dopamine Research: Success of Three Decades of Research Collaboration

Between the Medical University of Silesia in Poland and the Quillen College of Medicine at East Tennessee State

University in the USA. 17th

Neuropsychopharmacological Days, Ustro, Jaszowiec, Poland, 25-29 May 2008.

Pharmacol. Rep. 60: 254, 2008.

Nowak P, J Jochem, E Kőrössy, Ł Noras, RM Kostrzewa and R Brus (2008) Histamine level in the brain of

neonatally 6-OHDA-lesioned rats (rodent model of Parkinson’s disease). 17th


Ustro, Jaszowiec, Poland, 25-29 May 2008. Pharmacol. Rep. 60: 288, 2008.

Nowak P, R Szkilnik, E Kőrössy, Ł Noras, RM Kostrzewa and R Brus (2008) Effect of histamine receptor

antagonists on oral activity and stereotyped behaviors in neonatally 6-OHDA-lesioned rats (rodent model of

Parkinson’s disease). 17th

Neuropsychopharmacological Days, Ustro, Jaszowiec, Poland, 25-29 May 2008.

Pharmacol. Rep. 60: 288-289, 2008.

Nowak P, J Jochem, R Szkilnik, A Plech, E Korossy, L Noras, RM Kostrzewa and R Brus (2008) Histamine level in

the brain of rats with rodent model of Parkinson’s disease. Acta Biochimica Polonica 55 Suppl. 3, 195. From 43rd

Congress of Biochemistry and Cell Biology, Olsztyn, Poland, Sept. 7-11, 2008.

Nowak P, A Kwiecinski, RM Kostrzewa and R Brus (2009) Prenatal manganese and perinatal 6-hydroxydopamine

alter adulthood [3H]glucose uptake in rat brain. 4th

Neurotoxicity Society meeting, Arica, Chile, 24-26 April, 2009.

Nowak P, J Jochem, R Szkilnik, J Drab, RM Kostrzewa and R Brus (2009) Histaminergic activity in adult rats neonatally

lesioned with neurotoxins: DSP-4, 5,7-DHT and 6-OHDA. 4th Neurotoxicity Society meeting, Arica, Chile, 24-26 April,

2009.

Nowak P, J Jochem, R Szkilnik, E Kőrőssy, J Drab, K Bojanek, RM Kostrzewa and R Brus (2009) Histaminergic activity

in adult rats neonatally lesioned with neurotoxins: DSP-4, 5,7-DHT and 6-OHDA. 18th

Neuropsychopharmacological

Days, Ustroń, Jaszowiec, Poland 25-27 May, 2009.

Nowak P, J Jochem, R Szkilnik, E Kőrőssy, J Drab, K Bojanek, RM Kostrzewa and R Brus (2009) Histaminergic activity

in adult rats neonatally lesioned with neurotoxins: DSP-4, 5,7-DHT and 6-OHDA (rodent model of Parkinson’s

disease). 18th

Neuropsychopharmacological Days, Ustroń, Jaszowiec, Poland 25-27 May, 2009.

Nowak P, J Drab, R Szkilnik, E Kőrőssy, J Konecki, K Bojanek, RM Kostrzewa and R Brus (2009) Thioperamide

effect on [3H]glucose uptake in the brain of adult rats neonatally lesioned with 5,7-dihydroxytryptamine. 18

th

Neuropsychopharmacological Days, Ustroń, Jaszowiec, Poland 25-27 May, 2009.

Kostrzewa RM, R Brus, P Nowak, JP Kostrzewa (2009) Stereotypic progressions in psychotic behaviour. Fundacion

Cerebro y Mente meeting on ‘Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and

Treatment’, Mojacar, Spain, October 2009.


Szkilnik R, P Nowak, K Bojanek, RM Kostrzewa, R Brus (2010) Ontogenetic exposure of rats to pre- and post-natal

manganese enhances behavioral impairments produced by perinatal 6-hydroxydopamine. XVIIth International

Congress of the Polish Pharmacological Society, Krynica Zdrój, Poland, 16-18 Sept. 2010. Pharm. Reports 52

Suppl, p. 64.

Brus R, P Nowak, R Szkilnik, J Jochem, RM Kostrzewa (2010) Histaminergic activity in adult rats with neonatally

lesioned central noradrenergic, serotoninergic and dopaminergic (rodent model of Parkinson’s disease) systems.

XVIIth International Congress of the Polish Pharmacological Society, Krynica Zdrój, Poland, 16-18 Sept. 2010.

Pharm. Reports 52 Suppl, p. 107.

Kostrzewa RM (2010) Animal Models of ADHD, CME Program on “ADHD: From Basic Science to Bench Side” at

10th

Annual Meeting of the Safety Pharmacology Society. Boston, MA, 20-23 September 2010.

Brus R, J Jochem, P Nowak, R Szkilnik, RM Kostrzewa (May 2011) Histamine content in rat brains with rodent

model of Parkinson’s disease exposure to manganese during pre- and postnatal development. 20th

Neuropsychopharmacological Days, Ustroń, Jaszowiec, Poland. Pharmacol. Rep. 63: 589.

Kostrzewa RM, P Nowak, R Brus, RA Kostrzewa, JP Kostrzewa (Oct 2012) Hydroxyl radicals in striatum of

parkinsonian rats. Society for Neuroscience meeting, New Orleans LA, 13-17 Oct 2012.

Kostrzewa RM (March 2013) The dopamine D2 agonist quinpirole as a non-neurodegenerative neurotoxin. VI

Neurotoxicity Society meeting, Valdivia, Chile, 20-24 March, 2013.

Kostrzewa RM (May 2013) The changing face of neurotoxins. XVIII International Congress of the Polish

Pharmacological Society, Kazimierz Dolny, Poland, 22-25 May 2013.

Kostrzewa RM (June 2013) Dopamine D2 receptor supersensitization – effect on dopamine release and actions. 11th

World Congress of Biological Psychiatry, Kyoto, Japan. 23-27 June 2013.

Kostrzewa RM (August 2013) Amorphous Selective Neurotoxins. 11th International Symposium on VIP, PACAP

and Related Peptides, Pecs, Hungary, 26-31, 2013.

january 2014 curriculum vita richard m. kostrzewa, ph.d. · r.m. kostrzewa, ph.d. journal and book...

Documents